The Challenge of Articular Cartilage Repair : Studies on Cartilage Repair in Animal Models and in Cell Culture by Salonius, Eve
Doctoral Program of Clinical Research
Faculty of Medicine
University of Helsinki
Finland
THE CHALLENGE OF ARTICULAR
CARTILAGE REPAIR
STUDIES ON CARTILAGE REPAIR IN ANIMAL MODELS AND IN CELL CULTURE
Eve Salonius
ACADEMIC DISSERTATION
To  be  presented,  with  the  permission  of  the  Faculty  of  Medicine
of  the  University  of  Helsinki,  for  public  examination  in  lecture  room  PIII,
Porthania, Yliopistonkatu 3, on Friday the 22nd of  November,  2019  at  12
o’clock.
Helsinki 2019
Supervisors: Professor Ilkka Kiviranta, M.D., Ph.D.
Department of Orthopaedics and Traumatology
Clinicum
Faculty of Medicine
University of Helsinki
Finland
Virpi Muhonen, Ph.D.
Department of Orthopaedics and Traumatology
Clinicum
Faculty of Medicine
University of Helsinki
Finland
Reviewers: Professor Heimo Ylänen, Ph.D.
Department of Electronics and Communications
Engineering
Tampere University of Technology
Finland
Adjunct Professor Petri Virolainen, M.D., Ph.D.
Department of Orthopaedics and Traumatology
University of Turku
Finland
Opponent: Professor Leif Dahlberg, M.D., Ph.D.
Department of Orthopaedics
Lund University
Sweden
The Faculty of Medicine uses the Urkund system (plagiarism recognition) to
examine all doctoral dissertations
© Eve Salonius 2019
ISBN 978-951-51-5613-6 (paperback)
ISBN 978-951-51-5614-3 (PDF)
Unigrafia
Helsinki 2019
3ABSTRACT
Articular cartilage is highly specialized connective tissue that covers the ends
of bones in joints. Damage to articulating joint surface causes pain and loss of
joint function. The prevalence of cartilage defects is expected to increase, and
if untreated, they may lead to premature osteoarthritis, the world’s leading
joint disease. Early intervention may cease this process.
The first-line treatment of non-surgical management of articular cartilage
defects is physiotherapy and pain medication to alleviate symptoms. The gold
standard of surgical treatment is marrow stimulation, in which cells from bone
marrow migrate to the defect site and form a fibrin clot that is later replaced
by a fibrocartilaginous scar. More recent techniques include osteochondral
grafting and cell-based techniques. Autologous chondrocyte implantation
(ACI) is a surgical technique in which the patient’s cartilage cells are expanded
in laboratory and seeded under a periosteal flap. Biomaterial scaffolds have
been studied in replacing the periosteum and creating a supporting structure
for regenerating cartilage tissue. Despite promising short term results, a
material that is able to support the formation of durable hyaline cartilage is yet
to be developed.
This thesis was undertaken to improve current surgical cartilage repair
methods by testing the feasibility of novel biomaterial scaffolds in the repair
of cartilage and subchondral bone defects, as well as the use of animal models
in cartilage repair research.
Type II collagen is the most common fiber structure in articular cartilage.
The  feasibility  of  a  novel  composite  material  rhCo-PLA  that  combines
recombinant human type II collagen and poly(L/D)lactide felt was tested in a
porcine model. The scaffold was used in combination with autologous porcine
chondrocytes in the treatment of full-thickness chondral defects in the porcine
knee.  The  novel  scaffold  resulted  in  repair  tissue  with  similar  histology,
biomechanics and subchondral bone structure as a clinically used commercial
porcine type I/III collagen membrane. Subchondral bone lesions beneath the
repair site developed in all study groups but the novel scaffold resulted in fewer
bone defects than the commercial collagen membrane.
In conjunction with deep cartilage defects, the underlying subchondral
bone might be damaged as well. These bone defects might require filler
material  in  order  to  restore  the  height  of  the  cartilage  surface  and  joint
congruence. We aimed at improving the repair of cartilage–bone defects with
new bone filler materials. Therefore, a lapine model was used to evaluate the
repair of deep osteochondral defects with porous poly-lactic-co-glycolic acid
(PLGA) scaffolds and scaffolds combining PLGA with bioactive glass fibers.
PLGA resulted in bone volume fraction similar to that of spontaneous healing.
Combining  PLGA  with  bioactive  glass  worsened  the  repair  and  histological
evaluation revealed that the defects were filled with loose connective tissue
4instead of bone. Commercial controls, granular beta-tricalcium phosphate (β-
TCP) and bioactive glass (BG), resulted in extensive bone formation with no
signs of granular detachment.
Animal models are used in the development of new treatment options. In
order to improve the effectiveness and ethical use of the equine model in
articular cartilage repair, spontaneous repair capacity of equine carpal
cartilage  was  evaluated  to  find  the  critical  lesion  size  beyond  which
spontaneous repair does not occur. Surgically created circular chondral and
osteochondral defects were evaluated after 12 months of spontaneous repair.
Superficial chondral defects showed no bone cysts beneath the defect area but
in osteochondral defects, bone defects were found in all defect sizes (2 mm, 4
mm  and  8  mm).  Based  on  MRI,  μCT,  polarized  light  microscopy,
immunohistochemistry and standard histology, 2 mm was considered the
critical chondral lesion size and 4 mm the critical size of osteochondral defects.
Autologous chondrocytes have been used in cartilage repair for more than
20 years. The main limitations of the traditional chondrocyte implantation
technique are the limited amount of cells available and the requirement of two
separate surgeries. Bone marrow-derived human mesenchymal stem cells
(BM-MSCs)  can  be  used  as  an  alternative  cell  source.  Predifferentiation  of
these  cells  in  biomaterial  scaffolds  might  improve  the  repair  results.  Thus,
chondrogenic differentiation of BM-MSCs in three-dimensional biomaterials
was evaluated in an in vitro study.  Passage  3  BM-MSCs  were  cultured  in  a
chondrogenic  culture  medium  for  14  and  28  days  in  rhCo-PLA  scaffolds
manufactured  either  with  recombinant  human  collagen  type  II  or  type  III.
Commercial collagen membrane served as a control. The chondrogenic
differentiation resulted in chondrocyte hypertrophy at an early phase of cell
culture. The different collagen types in rhCo-PLA scaffolds did not affect the
outcomes.
In  conclusion,  the  novel  rhCo-PLA  scaffold  performed  well  in  a  porcine
model but the new PLGA-based bone filler materials were unable to produce
desired repair tissue in a lapine model. Critical defect diameter in the equine
carpus  was  defined  to  be  2  mm  for  chondral  and  4  mm  for  osteochondral
defects. The chondrogenic differentiation of BM-MSCs cultured both in the
rhCo-PLA scaffold and on commercial type I/III collagen membrane lead to
cell hypertrophy. All animal models used in this study, i.e., the porcine, lapine
and equine model, demonstrated that subchondral bone defects are associated
with cartilage defects and repair procedures. This emphasizes the fact that the
synovial  joint  is  a  functional  unit  comprised  of  several  tissues  and  the
challenge  of  cartilage  repair  is  further  complicated  by  comorbidities  in  the
adjacent tissues.
5TIIVISTELMÄ
Nivelrusto on korkeasti erilaistunutta sidekudosta, joka peittää toisiinsa
niveltyvien luiden päitä. Rustovauriot aiheuttavat kipua ja nivelen
toimintahäiriöitä ja niiden prevalenssin odotetaan kasvavan. Hoitamattomina
rustovauriot voivat johtaa ennenaikaiseen nivelrikkoon, joka on maailman
yleisin nivelsairaus. Aikaisella puuttumisella voitaneen ehkäistä tätä
kehityskulkua.
Rustovaurioiden konservatiivisen ensilinjan hoitoja ovat fysioterapia ja
kipulääkitys, joilla voidaan lievittää vaurioihin liittyviä oireita. Kirurgisten
toimenpiteiden kultaisena standardina pidetään luuydinstimulaatiota, jossa
luuytimen solut muodostavat säierustoisen arven vaurioalueelle. Uudempia
tekniikoita ovat osteokondraaliset siirteet ja soluterapiat. Autologinen
rustosolusiirre (autologous chondrocyte implantation, ACI) on kirurginen
tekniikka, jossa potilaan omia rustosoluja viljellään laboratoriossa ja
istutetaan luukalvon alle vaurioalueelle. Biomateriaali-istutteita on tutkittu
luukalvon korvikkeena. Huolimatta lupaavista lyhyen aikavälin tuloksista
vielä ei ole pystytty kehittämään materiaalia, joka pystyisi turvaamaan
kestävän lasiruston muodostumista.
Tämän tutkimuksen tarkoituksena on parantaa tämänhetkistä kirurgista
rustovauriokorjausta selvittämällä uusien biomateriaali-istutteiden
toimivuutta nivelruston ja rustonalaisen luun vaurioissa sekä parantaa
eläinmallien käytettävyyttä rustovauriokorjauksen tutkimuksessa.
Tyypin II kollageeni on nivelruston yleisin säierakenne.
Rekombinanttitekniikalla valmistettua tyypin II kollageenia ja poly(L/D)-
laktidia yhdistävän rhCo-PLA-komposiittibiomateriaalin toimivuutta
selvitettiin suureläinmallissa. Istutetta käytettiin yhdessä sian kondrosyyttien
kanssa koko rustokerroksen kattavan sian polven rustovaurion korjauksessa.
Uuden istutteen avulla muodostunut korjauskudos oli histologialtaan,
biomekaniikaltaan ja allaolevan subkondraaliluun rakenteelta samankaltaista
kliinisessä käytössä olevan kaupallisen sian tyyppi I/III kollageenista
valmistetun kalvon avulla muodostuneen korjauskudoksen kanssa.
Rustonalaisen luun vaurioita esiintyi kaikissa tutkimusryhmissä mutta
uudella istutteella korjatuissa rustovaurioissa luuvauriot olivat
harvinaisempia kuin kaupallisella kollageenikalvolla korjatuissa vaurioissa.
Syvien rustovaurioiden yhteydessä myös rustonalainen luu saattaa
vaurioitua.  Nämä luuvauriot saattavat vaatia luunkorvikemateriaalia
rustopinnan korkeuden ja nivelen kongruenssin palauttamiseksi. Pyrimme
parantamaan rusto–luuvaurioiden korjausta kehittämällä uusia luun
täyttömateriaaleja. Syvien osteokondraalivaurioiden korjausta tutkittiin
kanimallissa huokoisella poly-lactic-co-glycolic acid (PLGA) -istutteella sekä
PLGA:ta ja bioaktiivista lasia yhdistävillä istutteilla tutkittiin kaniinimallissa.
PLGA:n avulla aikaansaatu luun tilavuusosuus (bone volume fraction) vastasi
6spontaania korjautumista. PLGA:n ja bioaktiivisen lasin yhdistelmä heikensi
korjaustulosta, ja histologinen tarkastelu paljasti, että tässä ryhmässä vauriot
täyttyivät löyhällä sdekudoksella luun sijaan. Kaupalliset kontrollimateriaalit,
rakeinen beeta-trikalsiumfosfaatti (β-TCP) ja bioaktiivinen lasi (BG) johtivat
laajaan luunmuodostukseen ilman viitteitä rakeiden irtoamisesta.
Eläinmalleja käytetään uusien hoitomuotojen kehitystyössä. Hevosten
tehokkaan ja eettisen käytön parantamiseksi hevosen rannenivelen
rustovaurioiden spontaania parantumista arvioitiin tavoitteena löytää
kriittinen vauriokoko, jota suuremmat vauriot eivät korjaannu spontaanisti.
Kirurgisesti tehtyjen pyöreiden rusto- ja rusto-luuvaurioiden spontaania
korjaantumista arvioitiin 12 kuukauden seuranta-ajan päätteeksi.
Pinnallisissa rustovaurioissa luukystia ei todettu mutta rusto-luuvaurioissa
luun puutosta vaurioalueella todettiin halkaisijaltaan niin 2 mm, 4 mm kuin 8
mm kokoisissa vaurioissakin. Magneettikuvantamisen, mikrotietokone-
tomografia-kuvantamisen, polarisaatiomikroskopian, immunohistokemian ja
perinteisen histologian perusteella kondraalivaurioiden kriittisenä
vauriokokona pidettiin 2 mm halkaisijaa ja osteokondraalivaurioiden
kriittisenä kokona 4 mm halkaisijaa.
Autologisia kondrosyyttejä on käytetty rustovauriokorjauksessa yli 20
vuoden ajan. Perinteisen rustovauriosiirretekniikan tärkeimpinä rajoitteina
on rajallinen saatavilla olevan ruston määrä sekä kahden erillisen leikkauksen
tarve. Ihmisen luuydinperäisiä mesenkymaalisia kantasoluja (bone marrow-
derived mesenchymal stem cells, BM-MSCs) voidaan käyttää vaihtoehtoisena
solulähteenä. Näiden kantasolujen esierilaistaminen biomateriaali-istutteessa
saattaisi parantaa korjauskudoksen laatua. Näin ollen arvioimme
kantasolujen rustoerilaistumista kolmiulotteisissa istutteissa in vitro. Joko
tyypin II tai tyypin III kollageenillä valmistettuihin rhCo-PLA-istutteisiin
siirrostettuja kolmannen solujakautumisen kantasoluja viljeltiin
rustoerilaistamisliuoksessa 14 ja 28 päivän ajan. Kontrollina käytettiin
kaupallista tyypin I/III kollageenikalvoa. Rustoerilaistaminen johti
rustosolujen hypertrofiaan soluviljelyn aikaisessa vaiheessa. RhCo-PLA-
istutteiden kaksi erilaista kollageenityyppiä eivät vaikuttaneet
lopputulokseen.
Yhteenvetona voidaan todeta, että uusi rhCo-PLA-istute toimi hyvin
sikamallissa mutta uudet PLGA-pohjaiset luuntäyttömateriaalit eivät
tuottaneet toivottua korjauskudosta kaniinimallissa. Hevosen rannenivelen
kriittiseksi vauriokooksi määritettiin 2 mm rustovaurioille ja 4 mm rusto-
luuvaurioille. Sekä rhCo-PLA-istutteessa että kaupallisella tyypin I/III
kollageenikalvolla viljeltyjen luuydinperäisten kantasolujen
rustoerilaistaminen johti solujen hypertrofiaan.
Synoviaalinivel muodostaa toiminnallisen yksikön ja rustovaurion
korjauksen haastetta vaikeuttaa entisestään rustoa ympäröivien kudosten
vauriot. Tämä tutkimus osoitti, että rustovaurioihin ja niiden korjaukseen
liittyvät rustonalaiset luuvauriot ovat yleisiä sioilla, hevosilla ja kaniineilla.
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1 INTRODUCTION
Articular cartilage is highly specialized connective tissue covering the ends of
bones in joints. Cartilage provides joints with low-friction articulating surface
and acts as a shock absorber, allowing for painless movement of joints. Injuries
to articular cartilage are common and affect people of all ages. They can arise
as  a  consequence  of  joint  torsion  injury,  fracture,  or  repetitive  loading.
Articular  cartilage  defects  of  the  knee  have  a  prevalence  of  11–66%  in
arthroscopy data (Curl et al. 1997, Hjelle et al. 2002, Aroen et al. 2004, Mor et
al. 2015, Everhart et al. 2019). It is estimated that 11% of cartilage injuries
documented  in  arthroscopies  are  suitable  for  surgical  repair  (Aroen  et  al.
2004). As cartilage is known for its poor repair capacity, the injuries have a
tendency  to  progress  to  osteoarthritis  (OA),  which  is  associated  with
significant pain and loss of joint function. In Finland, the annual cost of OA
accounts for 0.5% of the gross national product (Heliövaara 2008).
Several surgical techniques have been developed in attempt to repair the
damaged  cartilage  and  to  prevent  the  progression  of  OA.  In  attempt  to
regenerate healthy articular cartilage, biodegradable materials have been
developed,  to  function  as  a  scaffold  and  provide  the  damaged  tissue  with
structural support. Biomaterial scaffolds can be used together with autologous
or allogenic cells to improve the healing response. Although cell therapy has
improved clinical outcomes of cartilage repair, several limitations associated
with these methods remain.
Development of new techniques to tackle the challenge of cartilage repair,
as  any  new  therapy,  relies  on  showing  their  safety  and  efficacy  in  animal
models  before  continuing  to  clinical  studies.  Each  animal  model  has  its
strengths and limitations, and it is crucial to understand these properties when
designing the study and choosing the animal model.
Despite rigorous research and short-term victories, restoration of the
complex  structure  of  fully  functional  articular  cartilage  still  remains  a
challenge. Improving biomaterial properties and enhancing neotissue
formation with the use of reparative cells could improve the results of cartilage
repair,  alleviate pain,  improve joint  functionality and delay,  or  even hinder,
the progress of post-traumatic OA. This study focuses on novel biomaterials
and  the  use  of  cell  therapy  both  in  cell  culture  and  animal  models  with  a
translational view from laboratory to clinical setting.
Review of the literature
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2 REVIEW OF THE LITERATURE
2.1 JOINT STRUCTURE
Synovial joints allow movement of limbs. The general structure of any synovial
joint is a synovial fluid-filled cavity where articular cartilage lines the ends of
articulating bones (Figure 1). A synovial capsule surrounds the joint. Synovial
membrane that lines the inside of the joint capsule is rich in vascular supply.
Synovial fluid, produced by the cells of the synovial membrane, lubricates the
articulating surfaces and provides nutrition to the cartilage (Buckwalter
2003). Articular cartilage is supported by subchondral bone, which consists of
subchondral  bone  plate  and  subchondral  trabecular  bone.  The  subchondral
bone plate includes calcified cartilage and underlying thin layer of cortical
bone (Burr 2004).
Figure 1 Schematic presentation of the knee joint.
2.1.1 COMPOSITION AND STRUCTURE OF ARTICULAR CARTILAGE
Articular  cartilage  (hyaline  cartilage)  covers  the  abutting  ends  of  bones  in
joints. It has pearly white macroscopic appearance. Due to its position in the
lever system and the vast forces that impact cartilage, its structure needs to be
substantially durable. Cartilage provides joints with a smooth, nearly
frictionless  gliding  surface  and  allows  load  bearing  and  shock  absorption.
These properties are due to the highly specialized structure of the tissue.  The
main  components  of  the  tissue  are  water,  collagens,  proteoglycans  and
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chondrocytes. The specific feature of articular cartilage tissue is that it lacks
innervation, blood vessels and lymphatic drainage. This leads to poor intrinsic
repair capacity (Buckwalter et al. 2005).
Most  of  the  articular  cartilage  tissue  is  composed  of  extracellular  matrix
(ECM). During embryonic development, cartilage tissue forms from the
mesenchyme as mesenchymal stem cells (MSCs) start to aggregate and
express  transcription  factor  SRY  (sex  determining  region  Y)-box  9  (SOX9),
which activates procollagen alpha 1 (II) gene and starts the chondrogenic
differentiation (Lefebvre 1997). Cartilage progenitor cells, chondroblasts,
produce  ECM  and  while  doing  so,  they  are  pushed  farther  away  from  each
other  by  the  matrix.  Residing  isolated  in  their  lacunae,  the  cells  are  called
chondrocytes.  Being  sparse,  chondrocytes  contribute  to  only  1–5%  of  the
tissue volume (Buckwalter 2003).
2.1.2 EXTRACELLULAR MATRIX
The dense ECM is composed of water, collagens, glycosaminoglycans (GAGs)
and proteoglycans (Figure 2). Water comprises 65–80% of tissue wet weight
and accounts for the shock absorbing function of cartilage (Mow et al. 1984).
Collagen proteins consist of three polypeptide chains, α chains, that coil into a
triple-helical  structure to form collagen fibers.  The main type of  collagen in
articular cartilage is type II collagen that constitutes approximately 90─95%
of articular cartilage collagen with type IV, V, VI, IX, X, and XI collagens as
minor components (Buckwalter 2003, Bhosale 2008).
Hyaluronan, chondroitin sulfate and keratan sulfate are the main GAGs in
articular cartilage. GAGs are long polysaccharides that have a negative charge,
attracting osmotically active cations. Sulfated GAGs, such as chondroitin
sulfate  and  keratan  sufate  bind  to  a  protein  core,  forming  proteoglycan
monomers,  aggrecans (Figure 2c).  Hyaluronan is  a  large non-sulfated GAG.
Aggrecan, the main type of articular cartilage proteoglycan, binds with a link
protein to a hyaluronan chain to form huge aggregates (Hardingham 1979).
One hyaluronan chain typically carries approximately 100 aggrecan
monomers, and the molecular weight of the aggregate is 108, or more (Mow et
al. 1984).
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Figure 2 Structure of articular cartilage. a) The zonal organization of articular cartilage
and subchondral bone. b) The extracellular matrix is composed of interstitial
fluid, collagen fibrils and proteoglycans. c) Glycosaminoglycans, mainly keratan
sulfate and chondroitin sulfate, bind to a protein core, which is attached to
hyaluronic acid with a link protein.
Cartilage is organized into four distinctive zones by ECM composition and
organization (Figure 2a). The superficial zone creates a smooth gliding surface
to the articular cartilage. The chondrocytes in this zone are flattened and the
collagen fibrils show high anisotropy and organization parallel to the surface,
protecting cartilage from shear forces. Unlike in other zones, type I collagen
may be present in the superficial zone. The superficial zone accounts for 10–
20% of cartilage thickness. (Buckwalter et al. 2005)
The  middle  or  transitional  zone  makes  up  approximately  40–60%  of
articular cartilage thickness. The middle zone contains oval cells, and collagen
fibers are organized obliquely (Fox et al. 2012, Buckwalter et al. 2005). The
chondrocytes reside at low density in chondrons that are surrounded by ECM.
The  deep  zone  consists  of  rounded  chondrocytes  that  are  organized  in  a
columnar fashion. The highest proteoglycan content and radial orientation of
collagen fibers in the deep zone provide protection from compressive forces
(Fox et al. 2012). Collagen content and collagen fiber size are the largest in the
deep zone and the zone represents approximately 30% of the tissue thickness.
The  deep  zone  is  separated  from  the  calcified  zone  by  a  tidemark,  a
mineralization front. Chondrocytes and collagen fibers in the calcified zone are
aligned similarly to the deep zone. Hypertrophic chondrocytes of the calcified
cartilage  express  hypertrophy  markers  such  as type X collagen, alkaline
phosphatase and matrix metalloproteinase-13. Hypertrophic chondrocytes
have the potential to differentiate into osteoblasts to form bone, or become
apoptotic, as in growth plates (Anderson 2003). The thick collagen bundles of
the deep zone continue to the calcified zone and anchor cartilage tissue to the
subchondral bone that lies beneath the calcified zone (Mow et al. 1984).
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2.1.3 CARTILAGE FUNCTION AND BIOMECHANICS
The mechanical  properties of  articular cartilage are closely dependent of  its
ECM composition (Mow et al. 1984, Lee et al. 2014). As proteoglycans have a
strong negative charge, they are responsible of the compressive strength of the
articular  cartilage  via  osmotic  pressure  and  swelling  of  the  cartilage  tissue.
Collagen fibrils limit the swelling and provide the tissue with tensile strength.
The mechanical response of articular cartilage is non-linear and dependent on
the loading type. Cartilage tissue biomechanics can be modeled as a biphasic
medium consisting of a fluid phase and a solid phase (Mow et al. 1984). The
extracellular matrix forms the solid phase, and water and inorganic ions form
the fluid phase. In biphasic model of cartilage, the solid phase can be further
divided to fibrillar modulus representing collagen fibers and non-fibrillar
modulus characterizes proteoglycans.
Application  of  force  on  cartilage  compresses  the  solid  matrix  and  causes
fluid  flux  out  of  the  ECM.  The  low  permeability  of  the  cartilage,  due  to
compressive stress created by the collagen fibril network and frictional drag of
the fluid flow, balances this fluid flow (Maroudas & Bullough 1968, Fox et al.
2012).  Constant  compressive  stress  makes  cartilage  tissue  deform  until
equilibrium strain is reached and fluid flow ceases. As the compressive loading
is removed, the hydrophilic, negatively charged proteoglycans of the cartilage
ECM have a higher ion concentration than synovial fluid. The Donnan osmotic
pressure difference enables the reabsorption of the water and swelling of the
cartilage to its original volume (Mow et al. 1984). This controlled water flux
leads  to  the  viscoelastic  and  shock-absorbing  properties  of  cartilage  and
provides nutrition to the avascular tissue.
The shear stiffness of articular cartilage is due to collagen cross-linking and
collagen–proteoglycan interaction (Fox et al. 2012). The parallel orientation
of the collagen fibrils in the superficial zone contribute the most to the shear
resistance and the perpendicular orientation and high proteoglycan content in
the deep zone account for the protection from the compressive stress. Thus,
the zonal cartilage structure contributes to the depth-dependent mechanical
properties of the tissue with compressive modulus increasing from 0.079 MPa
in the superficial zone to 320 MPa in the deep zone (Nooeaid et al. 2012).
Synovial joints are subject to high loads: human knee is subject to loads of
2.5 times body weight during walking and up to 10 times body weight when
running (Miller et al. 2015). Physiological loading is required for maintaining
normal cartilage function. Dynamic loading increases proteoglycan synthesis
through stretch-sensitive ion channels, and immobilization decreases GAG
content in cartilage ECM (Kiviranta et al. 1994, Bernhard & Vunjak-Novakovic
2016).  Aging and osteoarthritis  (OA) increase aggrecan turnover and soften
cartilage (DeGroot et al. 2001). Similarly, obesity, unphysiological joint
loading and repetitive stresses lead to cartilage damage (Buckwalter et al.
2013).
The  half-life  of  cartilage  aggrecan  is  3–24  years,  allowing  cartilage
proteoglycans  to  adapt  to  changes  in  joint  loading  in  healthy  cartilage
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(Maroudas et al. 1998, Verzijl et al. 2001). Collagen, by contrast, has a half-life
of more than 100 years, making disruption of collagen molecules irreversible
(Maroudas et al. 1998).
Since the mechanical equilibrium is dependent on the solid phase, loss of
proteoglycans and disorganization of collagen network lead to impairment of
biomechanical properties of the tissue. Cartilage repair procedures aim at
restoring the cartilage tissue organization and thus, its functional properties.
2.1.4 SUBCHONDRAL BONE
Subchondral  bone  is  located  directly  beneath  articular  cartilage,  providing
structural support. As an elementary tissue of the musculoskeletal system,
bone  serves  in  load-bearing,  locomotion  and  as  a  mineral  reservoir.  Bone
grows through endochondral ossification from cartilage formed during
embryogenesis. Unlike cartilage, bone is vascular tissue. The subchondral
bone  ECM  consists  of  water,  type  I  collagen  and  hydroxyapatite.  There  are
three cell types in bone tissue: osteoblasts, osteocytes and osteoclasts.
Osteoblasts, the bone forming cells, are responsible for ECM production and
mineralization (Han et al. 2018). They are of mesenchymal origin. Osteoblasts
that are entrapped by ECM become terminally differentiated osteocytes. They
are the most abundant cell type in bone. Osteocytes have a star-shaped
phenotype as they develop dendritic-like processes. They produce receptor
activator of NFκB ligand (RANKL) and monocyte colony-stimulating factor
(M-CSF) that regulate osteoclast differentiation. Osteoclasts are
multinucleated cells that are derived from hematopoietic monocyte-
macrophage lineage (Suda et al. 1992). Osteoclast is the sole cell type that is
capable  of  resorbing  bone.  They  attach  to  bone  with  integrins  and  through
proton  pump  and  chloride  channel  activity  they  create  an  acidic
microenvironment that degrades mineralized bone (Teitelbaum 2007).
Continuous  remodeling  by  the  counteractive  action  of  osteoclasts  and
osteoblasts maintains the balance between anabolism and catabolism,
allowing bone to adapt to changes in loading patterns (Christen et al. 2014).
2.1.5 JOINT HOMEOSTASIS
Joint homeostasis means the physiological equilibrium that maintains normal
tissue  milieu  in  the  joint  (de  Grauw  2011).  Continuous  tissue  turnover  is
needed to adapt to changes in external  conditions,  such as movement,  joint
loading, age, and hormonal influences. There is an increasing understanding
of joint homeostasis and the interaction of all synovial joint tissues, including
meniscus, ligaments, subchondral bone and synovium, in the proper cartilage
healing process (Grande et al. 1989, Buckwalter 2003, Gomoll et al. 2010).
Disruption of joint homeostasis is essential in pathogenesis of OA and other
joint degenerative diseases. Disturbances in joint homeostasis initiate
inflammatory, molecular and cellular changes in the joint, causing increased
21
matrix catabolism and decreased anabolism. Elevated concentrations of
proteoglycan fragments have been documented in both knees after unilateral
knee injury, indicating bilateral changes in cartilage metabolism (Dahlberg et
al. 1994). Macrophage-like cells in the synovium produce cytokines, such as
interleukin-1 and tumor necrosis factor-α, during inflammation and after joint
injury (Lee et al. 2009). Matrix metalloproteinases activated by cytokines
degrade ECM constitutents (Rose & Kooyman 2016). This degradation is the
earliest change seen in OA, and it reduces water retention of the tissue, leading
to diminished compression resistance as proteoglycan’s level of aggregation is
reduced. This appears as softening of the superficial zone and macroscopically
as thinning and fibrillation of the cartilage (Moskowitz et al. 2007).
Synovial membrane becomes thickened and increased in vascularity and
inflammatory cells in OA. Paracrine and autocrine signals transported via
synovial  fluid affect  tissue turnover and joint  homeostasis  (de Grauw 2011),
and synovial inflammation is typically seen in advanced OA (Loeser et al.
2012). Vascularization of the menisci has also been associated with OA (Loeser
et al. 2012).
 Articular cartilage is in close proximity to subchondral bone, as discussed
above. Diffusion of small molecules and cross-talk between articular cartilage
and bone marrow spaces has been shown in mice (Pan et al. 2009, Pan et al.
2012)  but  whether  this  cross-talk  takes  place  in  human  joints  is  debated
(Findlay & Kuliwaba 2016). Activation of endochondral ossification pathway,
including chondrocyte hypertrophy, is seen in early stage OA (Glyn-Jones et
al. 2015). The increased bone turnover leads to thickening of the subchondral
bone. Endochondral ossification leads to osteophytes, joint space narrowing,
subchondral  cysts  and  sclerosis,  and  these  features  have  been  used  in
radiographic classification of OA (Kellgren & Lawrence 1957).
Up  to  30%  of  a  joint  impact  is  conveyed  through  the  subchondral  bone
(Madry  et  al.  2010).  Intralesional  osteophytes  and  subchondral  bone  cysts
have been reported subsequent to cartilage damage and cartilage reparative
procedures  (Orth  et  al.  2013).  Callus  formation  and  stiffening  of  the
subchondral  bone  after  injury  affects  the  biomechanical  properties  of  the
repair cartilage and forces the articular cartilage to absorb a larger part of an
impact, which might accelerate its degeneration and predispose the joint for
OA (Costa-Paz et al. 2001). Walking on hard surface is demonstrated to cause
increased bone volume fraction and cortical stiffness of subchondral bone and
decrease the hexosamine content of cartilage, an early indicator of OA (Radin
et al. 1982).
Osteochondral  defects  might  have  a  small  degree  of  spontaneous  repair
capacity, as bone marrow cells are able to migrate to the defect area through
the subchondral plate penetration, although the repair tissue shows inferior
properties compared to healthy hyaline cartilage (Bhosale 2008). Subchondral
bone and articular cartilage form a functional osteochondral unit, and
disruption of either one causes alterations in the other (Pan et al. 2009, Orth
et al. 2013).
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2.2 CARTILAGE INJURIES
As articular cartilage lacks innervation, some cartilage defects are
asymptomatic. The prevalence of cartilage defects is expected to increase, and
untreated  cartilage  defects  have  a  tendency  to  become  symptomatic  and  to
propagate  to  early-onset  OA  (Buckwalter  2003).  The  disabling  symptoms
associated with cartilage defects include pain, swelling and catching of the
joint (McAdams et al. 2010).
2.2.1 PREVALENCE AND ETIOLOGY
Cartilage  lesions  are  common.  They  vary  from  small  focal  defects  to  deep
osteochondral defects. Only a small part of these defects can be repaired with
current methods. The prevalence of chondral lesions is reported to be 61–66%
in earlier knee arthroscopy studies (Curl et al. 1997, Hjelle et al. 2002, Aroen
et al. 2004). A registry study examining knee arthoscopies in Denmark found
the  prevalence  in  arthroscopies  to  be  11%  (Mor  et  al.  2015).  The  overall
prevalence of full-thickness chondral defects in athletes’ knees has been shown
to  be  36%  (Flanigan  et  al.  2010).  More  recently,  the  prevalence  of  full-
thickness cartilage defects in knee arthroscopies of athletes under 40 years of
age varied between 24–36% (Everhart et al. 2019). Årøen and colleagues
suggested  that  11%  of  the  cartilage  injuries  might  have  been  suitable  for
cartilage  reparative  procedure  (Aroen  et  al.  2004),  whereas  in  a  Danish
registry study on arthroscopy-documented cartilage defects, 16.7% of knee
cartilage injuries were repaired surgically (Mor et al. 2015). A large part of all
cartilage defects occur in elderly people and they often represent the beginning
of OA. In the Framingham Osteoarthritis Study based on magnetic resonance
imaging (MRI) of the tibiofemoral joint of general population aged 50 years or
more,  cartilage  abnormalities  were  found  in  69%  in  knees  without
radiographic signs of OA (Guermazi et al. 2012).
The prevalence of cartilage deterioration is expected to increase rapidly in
the following decades as the population ages and the prevalence of obesity
increases (Woolf & Pfleger 2003, Heliövaara 2008). The incidence of cartilage
lesions  is  40/100  000,  according  to  a  Danish  registry  study  on  knee
arthroscopies during the years 1996–2011 (Mor et al. 2015). The incidence was
reported to increase by 2.8-fold from 1996 to 2011. Increased popularity of
high-demand sports and extreme sports predispose to knee injuries
(McAdams et al. 2010, Vannini et al. 2016), and increase in the incidence of
sports trauma in the pediatric population predisposes to cartilage trauma at
an even younger age (Seto et al. 2010) . A retrospective cohort study conducted
in Norway showed that the total incidence of cartilage surgery was 56/100 000
during 2008–2011 (Engen et al. 2015). Prosthesis surgery, high tibial
osteotomy and patients over 67 years of age were excluded in attempt to omit
OA patients from this number.
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Factors such as trauma, age, body mass index and unphysiological loading
have been associated with cartilage lesions (Buckwalter et al. 2013, Vannini et
al. 2016). Årøen and colleagues stated that the most common cause of hyaline
cartilage  injury  is  a  sports  trauma,  which  accounted  for  55% of  the  injuries
(Aroen et al. 2004). Prevention of sports injuries and other traumatic injuries
is important in diminishing the prevalence of articular cartilage lesions.
Damage to articular cartilage during normal loading may be due to changes
caused  by  aging  and  genetic  factors.  During  aging,  advanced  glycation
endproducts (AGEs) accumulate to articular cartilage proteins, decreasing the
natural turnover of extracellular matrix proteins and therefore worsening the
ability of cartilage to react to environmental changes (DeGroot et al. 2001).
While physiological loading is required for cartilage nutrition and it
improves cartilage matrix synthesis, repeated non-physiological joint loading
predisposes cartilage to early OA, as shown by Kellgren and Lawrence in the
1950’s in a cohort study where miners and cotton workers had more clinical
and radiographical OA than people with other occupations (Kellgren &
Lawrence 1958). In the same study, overweight was associated with a higher
risk of cartilage pathologies.
Joint homeostasis and health of the whole joint also affect cartilage lesions.
It has been known for long that meniscectomy and decreased joint congruence
such  as  varus  malalignment  impair  the  mechanics  of  the  joints  and  lead  to
increased risk of OA (Fairbank 1948, Sharma et al. 2010).
Osteochondral  fragmentation  and  loosening  may  also  be  due  to
osteochondritis dissecans, a joint disease typically affecting children and
adolescents  (Kessler  et  al.  2014).  Trauma  and  genetic  factors  have  been
proposed as underlying causes of the disease, although the etiology is probably
multifactorial (Richie & Sytsma 2013).
2.2.2 DIAGNOSIS
As articular cartilage lacks innervation, cartilage defects may present without
pain.  Locking  and  caching  of  the  joint,  stiffness  and  limited  function  are
symptoms associated with cartilage injuries (Buckwalter 2003, McAdams et
al.  2010).  The  diagnosis  of  cartilage  defects  requires  cartilage  imaging  or
diagnostic arthroscopy.
Conventional  radiographs  can  detect  bone  abnormalities  as  well  as  later
signs of cartilage disease such as joint space narrowing, osteophyte formation,
subchondral cysts and sclerosis (Kellgren & Lawrence 1957). Radiography can
also be used in evaluating the alignment of limbs. However, articular cartilage
cannot be seen with radiography and therefore it cannot be used in diagnosing
cartilage defects.
Arthroscopy is considered the gold standard of articular cartilage evaluation
(Hjelle  et  al.  2002).  It  provides  direct  visualization  of  the  tissue.  Although
minimally  invasive,  diagnostic  arthroscopy  carries  the  risk  of  complications
and is costly.
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Magnetic resonance imaging provides a non-invasive method of evaluating
articular  cartilage.  Conventional  MRI  sequences,  such  as  T1-weighted, T2-
weighted, proton density (PD), short tau inversion recovery (STIR), and
gradient  echo  (GE)  can  be  used  in  evaluating  morphological  changes  of
articular  cartilage  (Liu  et  al.  2019).  The  depth  of  cartilage  defect  can  be
evaluated with these techniques but their spatial resolution is limited and they
underestimate the size of cartilage defects when compared to arthroscopy
(Campbell et al. 2013).
T1 relaxation  time  describes  the  dephasing  rate  of  protons  in  the
longitudinal plane. T1 has a negative correlation with cartilage water content
(Nieminen et al. 2012). The use of this sequence in cartilage imaging is limited
with poor contrast between cartilage and fluid (Liu et al. 2019). T2 relaxation
time describes the dephasing rate of  protons in the transverse plane after  a
radio  frequency  pulse  (Guermazi  et  al.  2015).  T2 relaxation time gives
implications on the water content and collagen network of articular cartilage
(Nieminen et al. 2012). Similarly, the compositional T1ρ imaging technique can
be used to evaluate the collagen network and glycosaminoglycans of cartilage
without the use of contrast agents. T1ρ detects slow molecular motion and can
therefore be used in evaluating large macromolecules, such as proteoglycans
(Nieminen  et  al.  2012).  Delayed  gadolinium-enhanced  MRI  of  cartilage
(dGEMRIC, T1Gd)  is  a  well  validated  method  of  articular  cartilage  imaging
based on T1 relaxation measurement. It utilizes intravenous administration of
gadolinium diethylene triamine pentaacetic acid (Gd-DTPA2-), which
distributes inversely to the negatively charged glycosaminoglycans in the joint
(Bashir et al. 1996, Guermazi et al. 2015). Thus, it provides information on the
glycosaminoglycan  content  of  the  tissue  (Bashir  et  al.  1996).  Additionally,
sodium (Na-23) MR imaging, chemical exchange saturation transfer (CEST),
and diffusion-weighted imaging (DWI) are useful imaging techniques for
evaluation  of  the  proteoglycan  content,  although  they  are  not  used  in  the
clinical setting (Liu et al. 2019, Guermazi et al. 2015).
2.2.3 CLASSIFICATION
Cartilage lesions may be classified to focal chondral defects and osteochondral
defects affecting the subchondral bone. Pure chondral defects can be further
divided into partial-thickness and full-thickness defects. Full-thickness
defects comprise the entire depth of the cartilage layer, extending to the
subchondral bone but not penetrating it.
The  Outerbridge  classification  system,  developed  in  1961,  is  the  first
classification system for cartilage injuries (Outerbridge 1961). Its more recent
iteration, the International Cartilage Repair Society Chondral Injury
Classification  System  (ICRS)  is  the  recommended  and  currently  the  most
commonly used grading systems for cartilage lesions (International Cartilage
Repair  Society 2000).  The ICRS system classifies  cartilage defects  into four
stages according to their severity and depth (Table 1).
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Table 1. The ICRS cartilage injury classification.
Grade 0 Normal
Grade 1 Nearly normal Superficial lesions or softening, superficial fissures or cracks
Grade 2 Abnormal Lesions <50% of cartilage depth
Grade 3 Severely abnormal Lesions >50% of cartilage depth
Grade 4 Severely abnormal Osteochondral defects penetrating the subchondral bone
2.2.4 OSTEOARTHRITIS AND POST-TRAUMATIC OSTEOARTHRITIS
OA,  a  degenerative  disease  of  articular  cartilage,  is  the  most  common  joint
disease.  There  are  over  237  million  OA patients  globally,  and  its  worldwide
prevalence  in  over  60-year-olds  is  10% for  men and  18% for  women (Glyn-
Jones et al. 2015, Vos et al. 2016). OA is known to develop as a consequence of
several  biologic,  mechanical  and  structural  factors  that  affect  joint
homeostasis, but much of the processes responsible for the progression is still
unclear (Carbone & Rodeo 2017).
OA  is  a  progressing  disease  that  leads  to  premature  cartilage  loss  and
symptoms that impair the quality of life. However, the plateau stage between
the injury and development of OA varies and might be long (Carbone & Rodeo
2017).  Non-operative  treatment  options  include  physiotherapy  and  muscle
strengthening exercises as well as pain medication. The operative treatment
options for end-stage OA are joint replacement and osteotomies for selected
patient  groups  (Coventry  1973,  Brouwer  et  al.  2014).  Evidence  shows  that
arthroscopic debridement has no benefit in knee OA (Laupattarakasem et al.
2008).
Post-traumatic osteoarthritis (PTOA) is degeneration of articular cartilage
secondary to a joint injury. It has been estimated that PTOA accounts for 12%
of  overall  burden  of  OA  (Brown  et  al.  2006,  Carbone  &  Rodeo  2017).
Treatment of intra-articular fractures and good alignment of the joint surface
are also important factors in preventing PTOA. Since PTOA often affects
young, active adults, delaying the onset of OA is crucial (Gelber et al. 2000,
Flanigan et al. 2010).
2.2.5 SOCIETAL IMPACT AND COST
Cartilage lesions and OA have a tremendous social and economic impact to the
society. Cartilage injuries typically affect young and middle-aged, physically
active patients (Gelber et al. 2000). Advancing cartilage defects are associated
with pain, limitations in activities and reduced quality of life. Although some
early stage cartilage defects might be asymptomatic due to the aneural nature
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of the tissue, focal articular cartilage defects can affect the quality of life of a
patient as much as advanced OA (Heir et al. 2010).
In Germany,  the overall  cost  of  a  cartilage repair  ranges from 13 445€ to
21 204€, depending on the surgical technique. These costs include surgery and
hospital stays, imaging, physiotherapy and medication (Koerber et al. 2013).
As untreated cartilage defects have a tendency to propagate to OA, the
impact and cost of OA cannot be overlooked when evaluating the outcomes of
cartilage injuries. OA is the thirteenth most common cause of years lived with
disability  (YLD)  (Vos  et  al.  2016).  Both  the  prevalence  and  YLD  of  OA  are
increasing.  PTOA  has  an  increasing  prevalence  with  age.  YLD  of  OA  has
increased with 32.9% in the general population and 3.9% in age-standardized
YLDs during the years 2005─2015 (Vos et al. 2016). The suggested treatment
option  for  end-stage  OA  is  total  knee  arthroplasty  (TKA).  A  total  of  12  251
primary knee prosthesis operations were carried out in Finland in 2016 (THL
2018), and the number of the operations is increasing.
The cost of OA in Northern America, United Kingdom, France and Australia
accounts  for  1% to  2.5% of  gross  national  product.  In  Finland,  OA leads  to
annual cost of one billion euros in Finland, approximately 0.5% of the Finnish
gross national  product (Heliövaara 2008).  In addition to the direct  costs  of
OA,  there  is  an  eight  times  greater  indirect  cost  that  includes  loss  of
productivity, workforce absenteeism, early retirement, leading to reduced
taxation revenue (Hunter et al. 2014). Moreover, OA was the cause of 10% of
new Finnish disability pensions in 2017 (Eläketurvakeskus ja
Kansaneläkelaitos 2018). Thus, the overall cost of OA is often underestimated.
Successfull  treatment  that  would  reduce  disability,  preserve  the  joint  and
postpone  or  even  obviate  the  need  for  joint  arthroplasty  of  even  a  small
proportion  of  cartilage  defects  would  mean  considerable  health  care  cost
savings, and improve quality of life and activity level of those affected.
2.3 TREATMENT OF CARTILAGE INJURIES
The difficulty to treat damaged cartilage was noted as early as in 1743 (Hunter
1743). Due to the limited healing capacity and the societal and socioeconomic
burden caused by progressed cartilage defects and post-traumatic OA, there is
a high attempt to repair articular cartilage defects in an early phase.
Cartilage defects can be managed surgically and non-operatively. Symptom
relieving and non-surgical treatment strategies include pain relief with
paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) and physical
therapy to improve joint stability, muscle strength and neuromuscular control
(Vannini  et  al.  2016).  Rehabilitation  and  physical  therapy  are  also  an
important part of the aftercare of surgical procedures. Advanced cartilage
defects and osteoarthritis are also being treated with intra-articular injections
of corticosteroids, glucosaminoglycans and hyaluronic acid
(viscosupplementation). These injections are thought to improve the
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mechanical properties of synovial fluid (Peyron & Balasz 1974) and diminish
inflammatory cytokines in the joint (Wang et al. 2006). Injections of platelet-
rich plasma, blood with supraphysiological concentration of platelets, have
also been used as they possess non-inflammatory and anabolic properties, but
their clinical efficacy is being debated (Johal et al. 2019). Nutraceuticals, such
as glucosamine and chondroitin, lack clinical evidence and should not be used
(Runhaar  et  al.  2017).  Although  these  non-surgical  approaches  are  widely
used, they are incapable of producing new cartilage tissue and restoring joint
function in the long term. Therefore, surgery is required.
Cartilage repair surgery has evolved from simply removing loose particles
and lavaging the joint to current technically demanding procedures. At
present, surgical cartilage repair techniques include marrow stimulation,
osteochondral transfer, and chondrocyte implantation (Table 2). The choice of
the surgical treatment procedure depends on the age and possible previous
treatment attempts of the patient as well as the size and location of the defect
(de  Windt  et  al.  2009,  Nakagawa  et  al.  2016).  Although  several  different
surgical treatment options have been developed, no treatment has
demonstrated  superiority  over  another  in  long-term  studies  (Filardo  et  al.
2013).
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2.3.1 DEBRIDEMENT AND MARROW STIMULATION
Magnuson  was  the  first  to  describe  joint  debridement  (Magnuson  1941).
This  simple  procedure  involves  removal  of  loose  particles  and  leveling  the
uneven cartilage surface in an open arthrotomy. Debridement and joint lavage
aim at brief symptom relief rather than regenerating the articular cartilage
tissue. This method does not slow down the process of OA and it might lead to
degeneration of the remaining articular cartilage (Kim et al. 1991). Based on
the early debridement techniques, Johnson developed abrasion arthroplasty,
which  is  an  arthroscopic  technique  where  damaged  cartilage  and  the
superficial layer of subchondral bone is removed (Johnson 1986).
Spongialization  was  proposed  by  Ficat  (Ficat  et  al.  1979).  This  is  a  more
radical version of abrasion arthroplasty, as it involves removal of damaged
cartilage and the entire subchondral bone and reveiling spongiosa. It is now
known  that  subchondral  bone  plays  an  essential  role  in  the  mechanical
support of the joint, and this technique has been abandoned (Orth et al. 2013).
Marrow  stimulation  techniques  stimulate  cells  from  the  bone  marrow  to
migrate to the lesion bed and initially form a blood clot that is later replaced
by  a  fibrocartilaginous  scar.  In  1959,  Pridie  (Pridie  1959)  was  the  first  to
conceive the concept of drilling holes into the subchondral bone to promote
spontaneous healing response through marrow-derived cells in osteoarthritic
patients. In his original publication, Pridie recommended using a drill bit with
the diameter of ¼ of an inch (6.4 mm). The method of Pridie drilling has been
modified by Steadman who introduced microfracture technique (Steadman et
al. 1997). This treatment is performed with an arthroscopic awl, creating much
smaller holes, 2─3 mm in diameter, 3─4 mm apart. Using the awl eliminates
heat  necrosis  associated  with  drilling  (Steadman et  al.  1997).  Microfracture
has been considered the gold standard of cartilage repair, although this status
has recently been challenged due to the lack of standardized studies and high
scientific evidence (Frehner & Benthien 2018). However, it has remained the
most commonly used cartilage repair technique (Gobbi et al. 2014) and it is
often used as a control in clinical trials evaluating cartilage treatment methods.
A query study found out that 93.7% of all cartilage procedures performed by
recently trained orthopaedic surgeons in the United States were marrow
stimulation  procedures,  although  the  incidence  was  declining  (Frank  et  al.
2019). Microfracture can be performed arthroscopically, and its other benefits
are  technical  easiness,  low  costs  and  fast  mobilization  of  the  patient.  It  is
suitable  for  treatment  of  small  defects  (Table  2)  (Biant  et  al.  2015).
Microfracture  enables  58–66%  of  athletes  to  return  to  sports,  and  this  is
achieved  8±1  months  post  surgery  (Mithoefer  et  al.  2009a).  Sports
participation  continues  for  52±6%  of  the  patients  (Krych  et  al.  2017).
Microfracture provides improved clinical scores and decreased pain but
normal hyaline cartilage cannot be restored. The forming fibrocartilage is less
durable  than  hyaline  cartilage  and  the  good  initial  results  deteriorate  at  24
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months post surgery in most studies (Mithoefer et al. 2009b, Gobbi et al. 2014,
Makris  et  al.  2015).  Another  complication  of  microfracture  is  formation  of
subchondral cysts in up to 33% of the patients (Mithoefer et al. 2009b).
Chen and colleagues found out that deeper subchondral bone perforations
produced superior tissue quality (Chen et al. 2011). Thus, microfracture
procedure has recently been further improved with nanofracture technique
(Benthien  &  Behrens  2015),  in  which  a  one  millimeter  thick  needle  and
cannulated  pick  are  used  to  create  standardized  subchondral  bone
perforations that are smaller and deeper than in microfracture, to avoid bone
compaction around the awl perforations.
In addition, biomaterial scaffolds have been introduced to microfracture
technique  to  provide  the  matrix  with  mechanical  stability,  as  discussed  in
chapter 2.3.5.
2.3.2 OSTEOCHONDRAL TRANSPLANTATION
Osteochondral transplantation is a reconstructive cartilage procedure with
various subtypes. It can be performed with autologous or allogenic grafts from
a  donor.  The  axiom  of  these  procedures  is  that  the  transferred  tissue  is
immediately functional without maturation time.
Lexer was the first to describe joint allograft transplantation using fresh
amputated limbs (Lexer 1908) and cadaveric tissue (Lexer 1925). Gross and
colleagues used this technique for PTOA and tumor reconstruction (Gross et
al. 1975). Nowadays, fresh osteochondral allografts (OCA) can be used to treat
large cartilage defects. A whole joint specimen is collected and restored in
nutritive medium. In an athrotomy, a size-matched allograft osteochondral
plug is harvested from the donor and press-fitted to the host defect site. The
use of allografts obviates the donor site morbidity and does not limit the size
of  the  treatable  defect.  Ten-year  results  have  shown  improved  pain  and
function scores (Cameron et al. 2016). 88% of the patients are able to return
to sports, and this is achieved 10±3 months after the surgery (Mithoefer et al.
2009a, Krych et al. 2017). The survivorship of fresh allografts in distal femur
has been 91% at 10 years (Cameron et al. 2016, Raz et al. 2014) and 59% at 25
years  (Raz  2014).  Continued  sports  participation  at  preinjury  level  is  52%
(Mithoefer et al. 2009a).
Chondrocyte viability and matrix degeneration limit the use of frozen grafts,
whereas refrigerated grafts maintain a 67% chondrocyte viability for 44 days
(Pearsall  et  al.  2004).  The  risk  of  disease  transmission  is  decreased  by
screening the donor for infectious diseases. This screening, however, delays
transplantation and decreases cell vitality in the transferred plugs.
Osteochondral allografts have also been associated with fissuring and
delamination, which lead to poor outcome (Chahal et al. 2013).
Osteochondral autograft transplantation was first reported in 1964 by
Wagner (Wagner 1964). In the early 1990’s, Matsusue (Matsusue et al. 1993)
and Bobic (Bobic 1996) transplanted multiple osteochondral grafts. Bobic
31
named this method osteochondral autograft transplantation (OAT). Hangody
popularized this method by publishing his report on mosaicplasty (Hangody
et al. 1997), in which several small osteochondral plugs are harvested from a
low-weight-bearing area with a hallow burr and then transferred to the lesion
site. The gaps between the plugs are spontaneously filled with fibrocartilage.
Arthroscopic autologous osteochondral grafting has been reported with
good results  in short  term (Barber & Chow 2006) and in a long term study
evaluating patient reported outcomes (Hangody & Fules 2003). Return to
sports is fast (5±2 to 7±2 months post surgery) and achieved for over 90% of
the patients (Mithoefer et al. 2009a, Krych et al. 2017). The results have shown
worsening  and  degeneration  progression  in  longterm  studies  (Gudas  et  al.
2012, Filardo et al. 2015), with a failure rate of up to 55% in a 10-year follow-
up (Bentley et al. 2012). The autograft survival has been 62.5% at 9–10 years
(Tetta et al. 2010). Continued sports participation at preinjury level is 52±21%
at  7  years  post  surgery  (Krych  et  al.  2017).  The  main  limitations  of  this
technique are donor site morbidity and poor integration of the plugs with the
host tissue (Hangody & Fules 2003).
2.3.3 MINCED CARTILAGE FRAGMENTS
Single-step chondral repair by transferring cartilage fragments is a relatively
new method of cartilage repair. The fragments can be particulated juvenile
allograft cartilage (PJAC) or autologous fragments secured to the defect site
by a scaffold (CAIS,  cartilage autograft  implantation system) (Bonasia et  al.
2015). More clinical studies are still needed to evaluate their effectiveness.
The use of autologous cartilage fragments in the treatment of cartilage
defects was first described by Albrecth in a rabbit model (Albrecht et al. 1983).
The  clinical  operation  technique  was  first  described  by  Cole  and  colleagues
(Cole et al. 2011). Hyaline cartilage is first harvested from a low weight-bearing
area of the joint. The harvested cartilage is then particulated into 1 to 2 mm
pieces and dispersed onto a biodegradable scaffold by a device (DePuy Mitek).
Fibrin glue is used to secure the pieces on place. The CAIS construct is then
fixed to the cartilage lesion site with bioabsorbable staple anchors.
Juvenile chondrocytes possess a 100-fold ability to synthesize
proteoglycans compared to adult chondrocytes (Yanke & Chubinskaya 2015).
The  PJAC  procedure  relies  on  a  commercial  product  of  pieces  of  juvenile
cartilage, harvested from donors younger than 13 years. The cartilage pieces
are mixed with fibrin glue and then transplanted onto the cartilage defect.
PJAC has provided symptom alleviation in short to medium term (Buckwalter
et al. 2014, Bonasia et al. 2015, Wang et al. 2018) but it provides no additional
benefit  in the appearance of  cartilage in postoperative imaging (Wang et  al.
2018).  Several  issues  remain.  The  long-term  fate  of  the  juvenile  cartilage
fragments and the superiority of juvenile tissue over mature cartilage have not
been established, and the source of juvenile cartilage is a disadvantage due to
ethical considerations (Yanke & Chubinskaya 2015).
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2.3.4 CELL-BASED THERAPIES
2.3.4.1 Autologous chondrocyte implantation
Autologous chondrocyte implantation (ACI) is the first cell-based therapy for
articular cartilage repair. The concept was introduced in the 1980’s in a rabbit
model  (Grande  et  al.  1989).  In  October  1987,  the  first  ACI  procedure  was
performed in a human knee by Lars Peterson and colleagues in Gothenburg,
Sweden,  and  the  first  pilot  results  were  published  in  1994  (Brittberg  et  al.
1994). In this two-stage surgical procedure, the patient’s own chondrocytes are
harvested from a less-weight-bearing surface of the femur. The cells are then
cultured in a laboratory to increase the cell yield. After 2─3 weeks, in a second
surgery, the defect site is debrided and a periosteum graft is sutured onto the
defect. The cultured chondrocytes are then injected underneath the graft with
a density of  0.5─1 million cells/cm2,  and the graft  is  then sealed with fibrin
glue to minimize cell leakage. Long-term studies have shown clinical
improvement (Minas et al. 2014) that is maintained for 20 years (Peterson et
al. 2010), as well as a satisfactory 20-year survival rate of 63% (Ogura et al.
2017).
The ACI method is technically challenging, costly, and the requirement of
autologous chondrocytes limit the use. Additionally, a long recovery time of
6─12 months after the surgery is required for the maturation of the neotissue
(Makris  et  al.  2015).  Return to sports  is  possible 18±4 months post  surgery
(Mithoefer et al. 2009a). Given these limitations, ACI accounted only for 2%
of all cartilage procedures were carried out with the ACI method in the public
sector  in  Norway  in  2008─2009  (Engen  et  al.  2015)  and  1.3%  of  cartilage
procedures carried out by recently trained orthopaedic surgeons in the United
States (Frank et  al.  2019).  Despite the limitations of  the method,  ACI is  the
recommended procedure for large chondral defects exceeding 4 cm2 (Table 2)
(Biant et al. 2015, National Institute for Health and Care Excellence (NICE)
2017).
2.3.4.2 Chondrocytes
In 1968, Chesterman and Smith were the first to isolate and transplant lapine
articular chondrocytes (Chesterman & Smith 1968). Their findings laid ground
to the development of ACI technique and autologous cell transplantation with
improved techniques has since been accepted for clinical use. Being the
naturally occurring cell of articular cartilage and surviving the anaerobic
environment of avascular cartilage, autologous chondrocyte is a widely used
cell  type  for  cartilage  repair.  Chondrocytes  are  phenotypically  right  without
the need to differentiate them, and they are able to produce the extracellular
matrix of cartilage tissue.
33
Requirement  of  two  separate  surgeries  is  the  major  shortcoming  of  this
method. The availability of chondrocytes is limited, leading to the need for cell
culture  to  expand  the  cell  yield.  This  is  a  concern  as  chondrocytes  have  a
tendency to dedifferentiate during cell culture expansion (Benya et al. 1978).
Previous in vitro studies with cadaveric human chondrocytes have confirmed
that  during  multiple  passaging  up  to  passage  6,  mRNA  levels  for  type  II
collagen decrease after each passage and type I collagen levels increase already
at passage 1 and remain high thoughout the passaging (Diaz-Romero et al.
2008).
2.3.4.3 Mesenchymal stem cells
The tendency of chondrocytes to dedifferentiate during cell culture has
sparked the search for novel cell sources. The presence of non-hematopoietic
stem cell population in bone marrow was first described by Friedenstien in the
late 1960’s (Friedenstein et al. 1966). Human mesenchymal stem cells
(mesenchymal stromal cells, MSCs), harvested from the posterior ilic crest of
volunteer donors, were first isolated and cultured by Haynesworth and Caplan
(Haynesworth et al. 1992). As defined by the International Society for Cellular
Therapy  position  statement,  MSCs  are  pluripotent  cells  that  are  defined  by
their adherence to plastic, their capacity to differentiate into several cell
lineages including osteoblasts, chondroblasts and adipocytes, and their
expression  of  certain  cell  surface  markers  (positive  for  CD73,  CD90  and
CD105;  negative  for  CD14,  CD11b,  CD79a,  CD34,  CD45  and  HLA-DR)
(Dominici et al. 2006, Murphy et al. 2013). Alongside bone marrow, which is
the  most  commonly  used  source  in  the  clinic,  MSCs  can  be  obtained  from
adipose tissue, dermis, periosteum and synovial membrane (Mollon et al.
2013).
Chondrogenic differentiation of MSCs in vitro has often been associated
with chondrocyte hypertrophy and entering ossification pathway (Chen et al.
2015). Still, MSCs attract great interest for cell-based cartilage repair therapy
due  to  their  easy  isolation,  high  proliferative  capacity,  and  ability  to
differentiate into chondrocytes and osteoblasts (Makris et al. 2015). MSCs also
maintain their chondrogenic capacity through multiple passaging (Yoo et al.
1998). Recent research suggests that instead of differentiating into building
blocks of repair tissue, the most important function of MSCs in cartilage repair
is their release of growth factors, cytokines and other trophic factors that guide
tissue  regeneration  (Murphy  et  al.  2013,  Caplan  2017).  Clinical  studies
utilizing both injected and scaffold-seeded bone marrow-derived MSCs have
shown good short-term results (Makris et al. 2015). Given these advantages,
MSCs hold great potential for cartilage regeneration.
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2.3.4.4 Other stem cells
Embryonic  stem  cells  (ESCs)  are  cells  with  the  ability  to  proliferate  in  an
undifferentiated state and later differentiate into any somatic cell (Thomson
et al.  1998).  Chondrogenesis  can be achieved by forming an embryoid body
and then selecting mesodermal cells, or by transforming ESCs into MSCs prior
to their chondrogenic differentiation (Hwang et al. 2008). The use of ESCs is
highly  debated  due  to  ethical  issues  regarding  cell  harvesting  and  teratoma
formation associated with the use of ESCs (Heng et al. 2004).
Ethical concerns of ESCs can be avoided by using induced pluripotent stem
cells (iPSCs). These cells are pluripotent cells derived from somatic cells such
as  skin  (Takahashi  &  Yamanaka  2006).  Their  pluripotency  is  achieved  by
virally  transducing  them  with  transcription  factors.  They  have  shown  good
chondrogenic differentiation potential and less chondrocyte hypertrophy than
chondrogenically differentiated MSCs in vitro and in vivo (Bernhard &
Vunjak-Novakovic  2016).  Limitations  of  iPSCs  are  inadequate  cell  yield  for
mass  production,  genomic  instability,  and  teratoma  formation  when
implanted (Mollon et al. 2013, Bernhard & Vunjak-Novakovic 2016).
2.3.5 SCAFFOLD-BASED THERAPIES
Culturing  chondrocytes  in  a  two-dimensional  plate  causes  them  to
dedifferentiate (Benya et al. 1978). This has initiated the development of three-
dimensional scaffolds, which are thought to reverse the dedifferentiation of
chondrocytes (Martinez et al. 2008), and to provide mechanical and structural
support  to  the  forming  repair  tissue  to  restore  function  at  the  damaged
cartilage area (Dhollander et al. 2011).
Biomaterials have been introduced to ACI to avoid cell suspension leakage,
periosteal flap hypertrophy and lengthy operation time of the first generation
method described in the 1990’s (Brittberg et al. 1994, Harris et al. 2010). In
the second generation ACI, a bilayer membrane produced of porcine type I/III
collagen  is  used  instead  of  the  periosteum  (Filardo  et  al.  2013).  The
biomaterial obviates the problems encountered with the graft, and a
statistically significant improvement in Lysholm and IKDC scores have been
reported in a matched-pair study comparing first and second generation ACI
at 10 years postoperatively (Niemeyer et al. 2014). Clinical results of second
generation ACI have been good up to 10 years postoperatively (Berruto et al.
2017). For first and second generation ACI, Mithoefer reported an average of
67%  return  to  sports  rate  (Mithoefer  et  al.  2009a),  whereas  in  their  meta-
analysis, Krych and colleagues found the rate to be 82% (Krych et al. 2017).
Third generation ACI (MACI; matrix-applied characterized autologous
cultured chondrocytes) utilizes constructs with cells implanted and grown on
an animal-originated type I/III collagen membrane before implantation and
the construct is secured in place with fibrin glue instead of sutures. This allows
for a more even cell spreading and provides the cells with a three-dimensional
environment and better structural support. Glue fixation improves the ease of
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use of the implant. The use of scaffolds enables repair of large cartilage lesions,
shortens procedure time, and improves surgical consistency (Saris et al. 2014).
MACI is the most common cartilage repair technique utilizing scaffolds and
cells (Makris et al. 2015) and it has shown improved KOOS as well as improved
defect filling in MRI at two and five years after the surgery (Saris et al. 2014,
Brittberg  et  al.  2018).  The  scores  were  higher  for  patients  receiving  MACI
treatment than for microfracture. The study, however, showed no statistically
significant difference in the defect filling when compared to microfracture
treatment.
Microfracture technique, the gold standard treatment for small cartilage
defects, has evolved with the introduction of scaffolds. Autologous matrix-
induced  chondrogenesis  (AMIC)  technique  combines  microfracture  with  a
bilayer porcine collagen membrane (Behrens 2005). The procedure was first
described by Behrens and colleagues in 2005. This procedure can be
performed within a single surgery and it permits treatment of larger defects
than the traditional microfracture technique. A study reporting mid-term
results  demonstrated  an  improvement  of  Lysholm,  ICRS,  Tegner  and
Cincinnatti scores at 48 months postoperatively (Gille et al. 2010). In a 5-year
RCT study comparing AMIC with microfracture, functional ICRS Cartilage
Injury  Standard  Evaluation  Form-2000  score  improved  from  92.3%  of
abnormal function to 66% in the microfracture treated group and from 100%
to 0–7% in the AMIC group five years after the surgery, although histological
evaluation  showed that  the  repair  tissue  in  both  microfracture-  and  AMIC-
treated  groups  was  fibrocartilage  (Volz  et  al.  2017).   Improved  IKDC  and
Lysholm  scores  were  also  reported  in  a  study  with  7  years  of  follow-up
(Schiavone Panni et al. 2018).
2.3.6 BONE GRAFTING
Bone grafting fills voids, promotes healing and provides mechanical support.
It has been estimated that the annual number of bone grafting procedures is
2.2 million in the world (Lewandrowski et al. 2000). Autologous bone, bone
graft taken directly from the patient, is considered the gold standard of bone
grafting  (Pape  et  al.  2010).  Cancellous  bone  is  most  often  taken  from  the
anterior or posterior iliac crest. Autograft harvesting may cause donor site
morbidity including pain, hemorrhage, nerve injury, and wound infection.
Allografts from tissue banks are usually taken from a cadaver donor or from
prosthesis surgery. Allografts carry the risk of disease transmission and
immunological  reactions.   Due  to  the  limitations  of  allograft  and  autograft
bone, tissue engineered bone fillers have been developed, as discussed in
chapter 2.4.2.
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2.3.7 CHOICE OF SURGICAL METHOD
The choice of surgical method depends on several factors, such as the size and
depth  of  the  cartilage  defect,  previous  repair  attempts,  and  the  age  and
physical demands of the patient (de Windt et al. 2009, Nakagawa et al. 2016).
The consensus of 104 surgeons based in the United Kingdom (UK) states that
articular cartilage defects smaller than 2 cm2 are suitable for treatment with
microfracture or osteochondral grafting, whereas defects larger than 4 cm2
should  be  repaired  with  cell-based  techniques  (Table  2)  (Biant  et  al.  2015).
According  to  the  guidelines  of  National  Institute  for  Health  and  Care
Excellence (NICE) of UK, only ACI is considered effective for treatments larger
than  2  cm2 if  non-surgical  treatment  does  not  alleviate  symptoms  (NICE
2017). Treatment of the smallest cartilage defects of <1 cm2 is not considered
beneficial (Biant et al. 2015).
2.4 BIODEGRADABLE BIOMATERIALS IN TISSUE
ENGINEERING
Biomaterials  are  defined  as  materials  that  are  “intended to interface with
biological systems to evaluate, treat, augment or replace any tissue, organ
or function of the body” (Nair & Laurencin 2007). They can be divided into
metals, ceramics and polymers. In medicine, they can be used as temporary
prostheses, scaffolds for tissue regeneration, and in drug delivery (Nair &
Laurencin 2007). In cartilage repair, they are used to restore the architecture
of the cartilage tissue and to support tissue growth. Multiphasic scaffolds that
combine biomaterials with different properties to match the architechture of
different cartilage layers or cartilage and subchondral bone are used to treat
osteochondral defects. Biomaterials used in tissue engineering applications
need  to  degrade  over  time  to  give  way  to  newly  formed  tissue,  be
biocompatible,  give  sufficient  mechanical  support,  and  not  cause
inflammatory or toxic reactions (Nair & Laurencin 2007, Bernhard & Vunjak-
Novakovic 2016).
Polymeric biodegradable biomaterials for tissue engineering can be in form
of gels, porous or fibrous scaffolds, or a combination of these. Hydrogels have
been developed to mimic the high water content of cartilage extracellular
matrix. They are made of natural or synthetic polymer networks that are rich
in  water  (Bernhard  &  Vunjak-Novakovic  2016).  They  should  have  good
biocompatibility, low friction and they are capable of maintaining the spheroid
shape of cells (Camarero-Espinosa & Cooper-White 2017). Hydrogels typically
have low mechanical strength limiting their use in weight-bearing applications
(Bernhard & Vunjak-Novakovic 2016). Porous and fibrous sponges and rigid
scaffolds have an improved mechanical strength, making them more suitable
in weight-bearing applications (Camarero-Espinosa & Cooper-White 2017).
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2.4.1 BIOMATERIAL SCAFFOLDS IN CARTILAGE REPAIR
2.4.1.1 Natural biomaterial scaffolds in cartilage repair
Based on their origin, biomaterials can be classified into natural and synthetic
materials. Natural biomaterials were the first biodegradable materials used in
a clinical  setting.  Natural  polymers are often extracted from animal tissues,
plants  or  algae.  They  have  good  bioactivity  and  they  can  be  degraded  and
remodeled  by  natural  pathways.  Natural  tissue  engineered  scaffolds  mimic
tissue environment. However, the major intrinsic limitation of these natural
materials is their inadequate mechanical strength, immunogenic responses
and batch-to-batch variation. (Nair & Laurencin 2007)
Carbohydrate-based materials, such as hyaluronan, chitosan and
polyethylene glycol, are highly hydrophilic cross-linked polymers. As
hyaluronan  is  an  important  component  of  extracellular  matrix  of
chondrocytes, hyaluronan hydrogels have good chondrocyte attachment
properties  (Bernhard  &  Vunjak-Novakovic  2016)  and  they  promote
mesenchymal  cell  differentiation  (Nair  &  Laurencin  2007).  Chitosan,  a
glucosamine polysaccharide typically derived from crustacean chitin, has
improved histological results when used together with microfracture to
stabilize  the  blood  clot,  as  compared  to  microfracture  alone  (Methot  et  al.
2016), and good clinical results at 5 years (Shive et al. 2015).
Protein-based materials, such as collagen, fibrin and gelatin, have good cell
attachment  properties.  Collagen  has  a  vital  role  in  the  normal  extracellular
matrix,  and  it  builds  the  base  for  the  most  commonly  used  biomaterials  in
cartilage tissue engineering (Filardo et al. 2013). Collagen-based biomaterials
have improved the results of cartilage repair in the ACI and AMIC methods
(Niemeyer  et  al.  2014)  with  type  I  collagen  being  the  most  commonly  used
collagen type in the scaffolds (Huang et al. 2016).
Collagen scaffolds are typically produced with bovine- or porcine-based
materials. Use of these xenogenic, i.e., animal-derived products, however,
carries the risk of  disease transmission,  the complex purification process of
collagen leads to batch-to-batch variation, and immunogenic responses are
possible  (Horwitz  et  al.  2002,  Heiskanen  et  al.  2007,  Yu  et  al.  2015).
Recombinant technique can produce animal component-free proteins in a
scalable, cost-effective manner and with uniform product quality (Baez et al.
2005).  Human  recombinant  type  II  collagen  has  been  successfully  used  in
cartilage repair in mouse and rabbit models (Pulkkinen et al. 2010, Pulkkinen
et  al.  2013a).  Although  recombinant  human  collagens  are  not  yet  used  in
treating cartilage defects in the clinic, there is clinical evidence on the safety
and  efficacy  of  the  use  of  recombinant  collagens  in  ophtalmic  applications
(Fagerholm et al. 2014).
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2.4.1.2 Synthetic biomaterial scaffolds in cartilage repair
Synthetic materials can be manufactured into different shapes and their
properties can be readily modified. Fabrication of synthetic polymers can be
scaled up to industrial-scale manufacturing. Polyesters, such as polylactic acid
(PLA) and polyglycolic acid (PGA) are frequently used synthetic bioabsorbable
materials  as  they  degrade  by  hydrolysis  of  ester  linkage.  (Nair  &  Laurencin
2007)
PLA is a synthetic polymer that is degraded by hydrolysis into lactic acid
and metabolized through the citric acid cycle. PLA contains methyl side groups
making it hydrophobic and thus reducing its degradation rate. PLA has a high
compressive  strength.  PGA  is  a  synthetic  polymer  that  also  degrades  by
hydrolysis but lacks methyl side groups and thus, it is more hydrophilic and
faster degraded than PLA. Copolymer of  PLA and PGA can be used in both
cartilage and bone repair (Uematsu et al. 2005, Pan et al. 2015).
Several other synthetic biomaterials have been proposed, although not
many of them have been used in the clinic. Polyglactin 910/poly-p-dioxanone
fleece together with fibrin solution has been used in MACI cartilage repair with
good clinical results and complete filling in 73% of patients after 48 months
post implantation (Kreuz et al. 2011).
Limitations of synthetic materials include low hydrophilicity and inferior
cell  attachment  properties  compared  to  natural  materials  (Bernhard  &
Vunjak-Novakovic 2016). Therefore, hybrid scaffolds combining synthetic and
natural components are being developed (Nair & Laurencin 2007).
2.4.2 BIOMATERIALS FOR SUBCHONDRAL BONE REGENERATION
Treatment of osteochondral defects is challenging due to the different
demands and dissimilar intrinsic healing capacity of cartilage and bone tissue.
The repair  material  should integrate well  to both the surrounding bone and
cartilage.  The  requirements  of  an  optimal  bone  filler  include  architectural
resemblance of natural bone and highly porous structure with interconnected
pores  that  allow  angiogenesis  and  tissue  infiltration  (Oryan  et  al.  2014).
Osteochondral scaffolds can be single-phased, or layered biphasic and
multiphasic to fulfill the requirements of both tissues (Kon et al. 2014). Only a
few clinical studies have investigated biomaterials intended for osteochondral
repair (Kon et al. 2018, Di Martino et al. 2015), although bone substitutes and
cartilage repair matrices have been extensively studied individually (Lopa &
Madry 2014).
2.4.2.1 Natural tissue engineered materials in bone regeneration
Bone  grafts  have  traditionally  been  decellularized  biologic  bone  grafts  that
retain the original bone architecture and have excellent biocompatibility
(Camarero-Espinosa & Cooper-White 2017). Demineralized bone matrix is
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allogenic or xenogenic bone where the mineral component has been removed.
It is one of the most popular bone graft substitutes with both osteoconductive
and osteoinductive properties (Gruskin et al. 2012). Tissue engineered
xenograft, have gained popularity due to their controllable properties as well
as superior biocompatibility and regenerative properties compared to
synthetic materials (Oryan et al. 2014). Immunological responses and batch-
to-batch variation are major disadvantages of using natural materials, as
discussed above.
Natural polymers, such as collagen, fibrin and chitosan are used in tissue
engineering of bone (Lee et al. 2014). Collagens, especially type I collagen as a
natural component of bone ECM, are non-toxic polymers with good
biocompatibility  and  high  availability  (Oryan  et  al.  2014).  Developed  for
osteochondral repair, a multilayered scaffold combining equine collagen and
hydroxyapatite has shown promising clinical results at a 2-year follow-up (Di
Martino et al. 2015, Kon et al. 2018).
2.4.2.2 Synthetic tissue engineered materials in bone regeneration
Inorganic materials, such as ceramics, calcium phosphates and bioactive
glasses promote biomineralization (Nooeaid et al. 2012). Calcium phosphate
ceramics, such as hydroxyapatite and β-tricalcium phosphate, are
osteoconductive  as  their  mineral  composition  is  similar  to  natural  bone
mineral  (Yu  et  al.  2015),  and  β-tricalcium  phosphate  is  resorbed  by
osteoclastic activity (Eggli et al. 1988). Bioceramics are easy to handle during
surgery, and they adapt to the bone cavity (Oryan et al. 2014). There is an over
30-year experience on their use in the clinical practice (Stahl & Froum 1986).
Osteoinduction has been reported on several calcium phosphate bioceramics
(Yu  et  al.  2015).  However,  brittleness  and  poor  mechanical  strength  might
limit their use in weight-bearing applications (Nooeaid et al. 2012).
Bioactive  glass  was  discovered  in  1969  and  introduced  to  the  class  of
bioceramics (Hench et  al.  1971).  Bioactive glasses are typically  composed of
silicon  dioxide,  sodium  oxide,  calcium  oxide,  and  phosphorus.  They  are
capable of forming direct bonds with bone, they promote osteoblast activity
(Lee et al. 2014), and even bacteriosidic properties have been reported
(Lindfors et al. 2010). Brittleness is a limitation of bioactive glass.
Poly(lactic-co-glycolic adic) (PLGA) can be manufactured with tailored
properties  by  varying  the  ratios  of  PLA and  PGA.  PLGA is  a  non-active  but
absorbable material typically used either to mechanically support the tissues
when applied as a solid implant or to create a surface for tissue formation when
applied as a highly porous scaffold (Muschler et  al.  2004).  It  is  suitable for
restoring both the bone and the cartilage unit of osteochondral defects (Lopa
& Madry 2014, Pan et al. 2015). PLGA is commercially available and exhibits
good mechanical strength (Oryan et al. 2014). Inflammatory responses due to
bulk hydrolysis of PLGA have been reported (Athanasiou et al. 1996).
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2.5 TRANSLATION OF NEW METHODS
Translation of new treatment options from bench to bedside requires the use
of  animal  models,  as  the  safety  and  efficacy  of  new  treatments  need  to  be
validated prior to clinical studies. Animal models are used in closing the gap
between in vitro laboratory  experiments  and  clinical  trials.  Evaluation  of
regenerative potential and possible immune responses of implants require the
use of animal models.
When  planning  animal  experiments,  the  ethical  principles  of  three  R’s
needs to be followed: Refinement, Reduction and Replacement (Russell &
Burch 1959). The number of animals used in experiments should be reduced
to  the  minimum.  Animal  models  should  be  replaced  with in vitro testing,
computer simulation or cadaveric experiments, when possible. Refinement of
experiments is essential to minimize the potential suffering of animals (Moran
et al. 2016).
In order to effectively use animal models in cartilage repair  research,  the
spontaneous healing capacity for each species needs to be known. Unlike
humans, animals typically show some cartilage repair capacity (Ahern et al.
2009). This needs to be taken into consideration when designing translational
animal experiments evaluating cartilage repair strategies. The lesion size
beyond which spontaneous repair  does not occur is  called the critical  lesion
size. The use of critical-sized lesions is justified for the efficacy of the study and
the ethical use of the animals.
2.5.1 SMALL ANIMAL MODELS
Animal  models  can  be  divided  into  small  and  large  animal  models.  Small
animals include mice, rats, and rabbits, which are used for proof-of-concept
testing of new theories. The advantages of using small animal models include
affordability, easiness of handling and housing, and the availability of
genetically modified strains (Moran et al. 2016).
Rodents, such as mice and rats, and rabbits are frequently used in cartilage
repair experiments. They provide information on degradation times and safety
profiles  of  implants (Moran et  al.  2016).  The articular cartilage in mice and
rats is very thin (Table 3), which does not allow for a realistic translation of the
results to humans (Ahern et al. 2009). Additionally, growth plates of rodents
remain  open  throughout  their  lives,  resulting  in  improved  intrinsic  repair
capacity (Libbin & Rivera 1989).
Chesterman was the first to study chondrocyte transplantation in a rabbit
model in the 1960’s (Chesterman & Smith 1968). The lapine model possesses
the advantages of small animal models and additionally it has a joint size that
is suitable for cartilage repair studies. This makes it the most commonly used
animal  model  in  musculoskeletal  research  and  a  popular  testbed  for
biomaterials  in  the  early  stage  of  translation.   However,  since  rabbits  have
higher metabolic activity and their joint loading and cartilage thickness differ
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from those of humans, the translational value of rabbits is lower than in large
animal models (Ahern et al. 2009, Moran et al. 2016).
2.5.2 LARGE ANIMAL MODELS
Large  animals  include  dogs,  goats,  sheep,  pigs,  and  horses.  They  have  an
appropriate joint size and cartilage thickness for cartilage repair research, and
they can be used for biocompatibility  studies as well  as  for  determining the
faith of a biomaterial within a defect (Moran et al. 2016).
Dogs  have  the  advantage  of  naturally  occurring  joint  diseases  that  are
similar to human, such as osteochondritis dissecans and OA. Arthroscopical
cartilage procedures and second look arthroscopies can be performed (Feczko
et al. 2003) and temporary immobilization, partial weight-bearing and
rehabilitation are possible (Kiviranta et al. 1994). Disadvantages of the canine
model are their relatively thin articular cartilage layer (Table 3), anatomical
differences  in  joints  and  ethical  considerations  due  to  their  status  as
companion animals (Moran et al. 2016).
Domestic  pigs  have  cartilage  thickness  and  architecture,  joint  size  and
loading similar to humans. This makes them an attractive experimental model
in cartilage repair research. However, pigs do not reach skeletal maturity until
2–4 years of age (Swindle 2007), and their husbandry is expensive. Therefore,
most research is carried out with skeletally immature pigs (Vasara et al. 2006).
Minipigs  can  be  obtained  from commercial  suppliers  and  their  adult  size  is
significantly smaller than domestic pigs, providing a good option for domestic
pigs (Moran et al. 2016).
Sheep  and  goats  are  easily  obtained  and  housed  and  arthroscopy  can  be
performed  (Brehm  et  al.  2006,  Ude  et  al.  2014).  Goats  have  joint  anatomy
close to human, and appropriate joint size and cartilage thickness that allow
for creation of chondral and osteochondral defects (Jackson et al. 2001, Moran
et  al.  2016).  Sheep  have  a  large  variation  in  their  cartilage  thickness.  Both
sheep and goats have a high risk of subchondral cyst formation (Jackson et al.
2001,  Moran et  al.  2016).  Equine models are advantageous due to the large
joint size, cartilage thickness closest to that of humans that allows for creation
of  partial-thickness  cartilage  defects  (Table  3)  (Moran  et  al.  2016).  Horses
suffer  from  cartilage  pathologies  similar  to  those  of  humans  and
arthroscopical methods can be applied (Malda et al. 2012). Naturally occurring
osteoarthritis in the horse are most common in the metacarpophalangeal and
carpal joints (McIlwraith et al. 2012). The equine model is challenging due to
its requirement of specialized habitat that leads to increased expenses, and
ethical issues due to its status as a companion animal.
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Table 3. Comparison of the most commonly used animal models in cartilage repair
research.
Species Skeletal
maturity a,b
Adult weight
a,d
Mean
cartilage
thickness a,c
Joints used c Critical
lesion
diameter a,c
Human 18?22 years 60?90 kg 2.4?2.6 mm 10 mm
Horse 24?48 months 500?600 kg 2.0?3.0 mm Knee, carpus, ankle 9 mm (knee)
Pig 24 months 250 kg 1.5?2.0 mm Knee 6 mm
Goat 48?36 months 40?70 kg 0.8?2 mm Knee ??7 mm
Dog 12?24 months 15?30 kg 0.95?1.3 mm Knee, shoulder, elbow,
hip, ankle
4 mm
Rabbit ??10 months ??4 kg 0.16?0.75 mm Knee, shoulder 3 mm
Rat Life-long 0.25?0.55 kg 0.1 mm Knee Unknown
* Critical lesion diameter is the size of a defect beyond which spontaneous repair does not occur.
References a (Moran et al. 2016), b (Ahern et al. 2009), c (Cook et al. 2014), d (Sengupta 2013)
2.6 REGULATION AND PATIENT SAFETY
Cartilage  repair  therapies  may  be  classified  as  medical  devices  or  advanced
therapy medicinal products (ATMPs), based on their origin, intended purpose
and principal  mechanism of  action.  A  medical  device  typically  functions  by
physical means, whereas a medicinal product acts through pharmacological or
metabolical means. Marketing authorization is required for all medical devices
and medicinal products regulated by the European Union (EU).
The European Union defines medical devices and medicinal products as
follows:
Medical device
"any instrument, apparatus, appliance, software, implant,
reagent, material or other article intended by the manufacturer to
be used, alone or in combination, for human beings for one or
more of the following specific medical purposes:
—diagnosis, prevention, monitoring, prediction, prognosis,
treatment or alleviation of disease,
—diagnosis, monitoring, treatment, alleviation of, or
compensation for, an injury or disability,
—investigation, replacement or modification of the anatomy
or of a physiological or pathological process or state,
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—providing information by means of in vitro examination of
specimens derived from the human body, including organ, blood
and tissue donations,
and  which  does  not  achieve  its  principal  intended  action  by
pharmacological, immunological or metabolic means, in or on the
human  body,  but  which  may  be  assisted  in  its  function  by  such
means.
The following products shall also be deemed to be medical
devices:
—devices for the control or support of conception;
—products specifically intended for the cleaning, disinfection
or sterilisation of devices as referred to in Article 1(4) and of those
referred to in the first paragraph of this poin."
(Regulation (EU) 2017/745)
Medicinal product:
—"Any substance or combination of substances presented for
treating or preventing disease in human beings.”
—“Any substance or combination of substances which may be
administered to human beings with a view to making a medical
diagnosis or to restoring, correcting or modifying physiological
functions in human beings is likewise considered a medicinal
product."
(Directive 2001/83/EC)
In order for a medical device to receive a marketing approval in the EU, the
product needs to carry a Conformité Européenne (CE) mark, which indicates
that the product complies with EU directives. The regulatory framework that
govern  market  access  to  the  EU  will  soon  be  changed  as  the  the  current
European Union Medical Devices Directive 93/42/EEC will be replaced by the
Medical Devices Regulation 2017/745 (MDR) that came into force on May 25 th
2017. Medical devices must meet the MDR requirements from May 26th 2020
in order to be placed on the market. Manufacturers whose devices have been
certified according to the Medical Devices Directive 93/42/EEC can continue
to place products on the market until May 26th 2024 on the condition that no
essential  changes  are  made  to  them  and  they  are  subject  to  continued
surveillance. (Regulation (EU) 2017/745)
The purpose of the regulation is to protect patients from possible risks of
medical devices. Competent Authority, such as National Supervisory
Authority  for  Welfare  and  Health  (Valvira)  in  Finland  and  Medicines  and
Healthcare  Products  Regulatory  Agency  in  the  United  Kingdom,  is  a
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governmental body that oversees device approval. Competent Authorities
designate NBs, typically private companies.
Based on the risks and intended use, medical devices are categorized into
four classes (class I, IIa, IIb, III) (Kramer et al. 2012). High-risk devices, such
as implantable materials, require assessment and European commerce (EC)
certification by a Notified Body (NB). Depending on selected conformity route,
the  NB  either  audits  the  manufacturer’s  quality  system  and  reviews  the
technical file of the device or performs type testing and product verification to
ensure the device meets its claims (Kramer et al. 2012, Van Norman 2016). A
class  I  low-risk  device,  however,  may  receive  market  approval  by  self-
certification and declaration of compliance coupled with product registration
without the review by an NB.  All manufacturers are required to maintain a
product technical documentation, quality management system and risk
management that is regularly updated. (Regulation (EU) 2017/745)
The European Medicines Agency (EMA) supervises and monitors the safety
of medicines in the European Union. ATMPs are medicines that are based on
gene  therapy  medicinal  products  (GTMPs),  somatic  cell  therapy  medicinal
products  (CTMPs),  tissue  engineered  products  (TEPs),  or  medical  devices
containing medicine (combined ATMPs). The European Commission
Regulation (EC) No 1394/2007 on Advanced Therapy Medicinal Products
(ATMP Regulation) together with Directive 2004/23/EC regulate cell and
tissue products in the EU. The EMA defines tissue engineered products (TEPs)
as products that contain or consist of “engineered cells or tissues” and have
properties for or are “used in or administered to human beings with a view to
regenerating, repairing or replacing a human tissue.” (Directive 2001/83/EC)
Cells and tissues are considered engineered in the regulation, if they have
been substantially manipulated by, e.g., cutting, shaping, centrifugation, cell
separation, sterilization, freezing, or if they are not intended to be used in the
same function in the recipient as in the donor. Thus, mesenchymal stem cells
and other cell therapy products are considered ATMPs in the EMA regulations
(Murphy & Barry 2015).   The ATMP regulations allow the use of  ATMPs in
treatment of  patients with hospital  exemption,  which can be granted by the
Member State if the use is non-routine-based and the ATMP is prepared
according  to  the  quality  standards  (Regulation  (EC)  No  1394/2007).  In
Finland, hospital exemption can be obtained from the Finnish Medicines
Agency  Fimea.  The  Finnish  Act  of  the  Medical  Use  of  Human  Organs  and
Tissues (101/2001) lays down provisions on the use of human cells and tissues.
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3 AIMS OF THE STUDY
The purpose of this study is to expand the body of knowledge associated with
cartilage lesions and their repair with novel methods. Therefore, the specific
questions to answer in this thesis are:
1 Is the new biomaterial scaffold rhCo-PLA able to support cartilage
repair in a porcine model? (I)
2 Can the novel PLGA-based biomaterials support bone growth in
the repair of deep osteochondral lesions in a rabbit model? (II)
3 What is the critical chondral and osteochondral lesion size in the
equine carpus? (III)
4 Can mesenchymal stem cells be chondrogenically differentiated in
a three-dimensional rhCo-PLA scaffold? (IV)
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4 MATERIALS AND METHODS
In  this  study,  three  individual  animal  experiments  were  conducted  to
investigate  the  spontaneous  cartilage  repair  and  the  ability  of  novel
biomaterials to enhance repair of articular surface defects. Additionally, one
in vitro experiment  was  conducted  to  find  out  whether  chondrogenically
predifferentiation of mesenchymal stem cells in biomaterials improves matrix
deposition by the cells and thus prepares the construct for implantation.
All  of  the animals,  biomaterials,  cells,  and analysis  methods used in each
individual study are listed in Table 4.
Table 4. Summary of the methods used in studies I?IV.
Animal Biomaterials Cells Imaging Histology Other methods
Study I Domestic pig rhCo-PLA,
pCo
Autologous
chondrocytes
μCT Saf-O,
Col1, Col2
Biomechanical
testing
Study II Rabbit PLGA,
PLGA-BGf,
?-TCP,
BG
? μCT Masson-
Goldner
trichrome
Histomorphometry
Study III Horse ? ? μCT, MRI Saf-O,
Col1, Col2
PLM
Study IV ? rhCo-PLA,
rhCo3-PLA,
pCo
BM-MSCs,
Chondrocytes
Confocal
microscopy
Saf-O,
Col1, Col2
qPCR,
sGAG/DNA,
rhCo-PLA, recombinant human type II collagen?poly(D/L)lactide scaffold; pCo, porcine type I/III collagen membrane;
PLGA, poly(lactide-co-glycolide) scaffold; PLGA-BGf, PLGA?bioactive glass fiber scaffold; ?-TCP, ?-tricalcium
phosphate granules; BG, bioactive glass; rhCo3-PLA, recombinant human type III collagen?poly(D/L)lactide scaffold;
BM-MSC, bone marrow-derived mesenchymal stromal cell; μCT, micro-computed tomography imaging; Saf-O,
Safranin-O staining; Col1, type I collagen; Col2, type II collagen; PLM, polarized light microscopy; qPCR, quantitative
PCR; sGAG/DNA, sulfated gycosaminoglycan/DNA.
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4.1 BIOMATERIALS (I, II, IV)
4.1.1 COMPOSITE SCAFFOLD RHCO-PLA (I, IV)
Composite  scaffold  rhCo-PLA  was  used  in studies I and IV. Recombinant
human type II collagen fibrils (rhCo) were manufactured from human type II
collagen produced with recombinant technique (Fibrogen Europe Ltd.,
Helsinki, Finland). Thin fibers of medical grade poly(L/D)lactide 96/4 (PLA)
(Corbion Purac,  Gorinchem, The Netherlands) was needle punched into a 1
mm thick felt in Tampere University of Technology (Tampere, Finland). The
felt was gamma sterilized at 25 kGy. The felt was cut into cylindrical discs with
a diameter of 8 mm. The PLA96/4 felt cylinders were immersed with collagen
solution and frozen in sample molds ad -30°C for 24h prior to freeze-drying
for 24h. The scaffolds were cross-linked with 95% ethanol solution with 14 mM
EDC (N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride,
Sigma-Aldrich, Helsinki, Finland) and 6 mM NHS (N-Hydroxysuccinimide,
Sigma-Aldrich). The rhCo-PLA composite scaffolds were then washed, freeze-
dried and packaged. Manufacturing and packaging of the rhCo-PLA scaffolds
was done in a laminar flow chamber to prevent contamination.
For study IV,  the rhCo3-PLA scaffolds were produced similarly but using
recombinant human type III collagen (Fibrogen Europe Ltd.) as the natural
component instead of type II collagen.
4.1.2 POROUS PLGA AND COMPOSITE SCAFFOLD PLGA-BGF (II)
PLGA (poly(lactide-co-glycolide)) was polymerized from medical grade D-
lactide  and  glycolide  (Corbion  Purac,  Gorinchem,  the  Netherlands)  and L-
lactide (Futerro, Escanaffles, Spain) by ring-opening polymerization in Åbo
Akademi  University  (Turku,  Finland).  The  PLGA  polymer  had  a  lactide  to
glycolide ratio of 7:3 with equal amounts of D- and L-lactide. The polymer was
purified by dissolution in dichloromethane and precipitation in ethanol. PLGA
was then extruded into approximately 2.8 mm thick rods that were cut to 16
mm long pieces. The pieces were placed in custom-made Teflon molds with an
inner diameter of 4.0 mm. The PLGA scaffolds were gas foamed in the molds
in a chamber with a carbon dioxide pressure of 55 bar for 10 h. Scaffolds with
the length of 8 mm and a mass of 24–27 mg were then cut from the foamed
rods and sterilized with gamma irradiation at 25 kGy.
PLGA-BGf composite scaffolds were produced from the above described
PLGA  polymer  and  bioresorbable  melt-derived  glass  fibers  (Vivoxid  Ltd.,
Turku,  Finland).  The bioactive glass fibers (BGf) had a composition of  68.6
SiO2, 12.5 Na2O, 9.3 CaO, 7.2 MgO, 1.8 B2O3 and 0.6 P2O5 (in mol-%) and
an  average  fiber  diameter  of  13  μm.  The  BGf  was  cut  into  staple  fibers  of
approximately 10 cm in length and carded into mesh. The PLGA polymer was
dissolved in 1,4-dioxane as 3 wt-% solution. The PLGA solution was immersed
into BGf carded mesh and the samples were frozen to -30°C for 24 h prior to
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24 h freeze-drying. The PLGA-BGf composite scaffolds were then cut into
pieces  and  five  parallel  pieces  were  glued  together  with  PLGA solution  and
freeze-dried again. The height of the final rod was 8 mm and diameter 4 mm.
The rods were gamma sterilized at 25 kGy.
4.1.3 COMMERCIAL PORCINE COLLAGEN MEMBRANE (I, IV)
Commercial collagen membrane (pCo) manufactured from porcine type I and
III collagens (Chondro-Gide®, Geistlich Pharma AG, Wolhusen, Switzerland)
was  used  as  a  control  scaffold  in studies I and IV.  It  is  one  of  the  most
frequently used biomaterial products in cartilage repair surgery (Brittberg
2010) and as such, it was considered to represent the gold standard.
4.1.4 COMMERCIAL BONE SUBSTITUTE MATERIALS (II)
Commercial  bioactive  glass  granules,  denoted  as  BG  (BonAlive®, BonAlive
Biomaterials Ltd, Turku, Finland) and commercial β-TCP granules (Synthes®
chronOS, Synthes GmbH, Oberdorf, Switzerland) were used as controls in
study II. The BG granules consisted of 53 SiO2, 23 Na2O, 20 CaO, and 4 P2O5
(in wt-%) and had a diameter of 0.5–0.8 mm. The size of the β-TCP granules
was 0.5–0.7 mm and the porosity of the material was 60%.
4.2 ANIMAL MODELS (??III)
For study I,  a  total  of  20 female domestic  pigs (Sus scrofa domestica) were
used. The pigs were 4 months old and obtained from a local farmer. All pigs
underwent a clinical health examination and were acclimatized to the new
environment  for  two  weeks  prior  to  the  operations.  The  animals  were
randomized into three groups: the rhCo-PLA treatment group received an
rhCo-PLA scaffold (n=7); the pCo treatment group received a pCo membrane
(n=7), and the spontaneous healing group was left untreated (n=6).
A  total  of  40  female  New Zealand  white  rabbits  (Oryctolagus cuniculus)
were obtained from a commercial supplier (Harlan laboratories B.V., Venray,
the Netherlands) for study II. The animals were 18 weeks old. They were
acclimatized for one week before the operations. The rabbits were randomized
into  five  groups  (n=8  in  each  group).  Four  of  the  groups  received  a  bone
substitute material (PLGA, PLGA-BGf, BG, or β-TCP) and one group was left
untreated for spontaneous healing.
Five 24-month-old horses (Equus caballus) were included in study III.
Circular full-thickness cartilage defects or osteochondral defects with a
diameter of 2, 4, 6, and 8 mm were created in the middle carpal joint. The 6
mm defects  were  used  for  other  studies  and  they  were  not  included  in  this
study (Kulmala et al. 2012, Viren et al. 2012, Rautiainen et al. 2013). All defects
were left untreated for evaluation of spontaneous healing response.
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4.3 SURGERIES (??III)
4.3.1 CHONDRAL INJURY AND REPAIR WITH ACI TECHNIQUE (I)
Two operations were carried out in pigs. The first operation was performed in
order to create the surgical cartilage defect and to acquire a cartilage biopsy
for  the  repair  operation.  The  pigs  were  sedated  with  0.2  mg/kg  (s.c.)
medetomidine and 10 mg/kg (s.c.) ketamine. Preoperative analgesia of 0.05
mg/kg (s.c.)  buprenorfin  and  3  mg/kg  (s.c.) carprofen as well as antibiotic
prophylaxis  of  3.0  g  (i.v.) cefuroxime was administered. Anesthesia was
induced  with  propofol  (i.v.)  and  maintained  with  1.5?2.5% isoflurane. The
animals were set in a supine position on the operating table. Through a medial
parapatellar arthrotomy, a single circular chondral lesion of 8 mm in diameter
was  created  on  the  central  area  of  the  medial  condyle  of  the  femur  with  a
biopsy punch (Stiefel Laboratories Ltd, Wächtersback, Germany). Cartilage
was removed to the level of the subchondral bone. The incision was closed in
layers. The animals were allowed free weight-bearing and unrestricted
movement after the operation. The operated pigs were housed separately for
three postoperative days and grouped thereafter. The harvested cartilage was
stored before chondrocyte isolation in sterile phosphate-buffered saline
solution (PBS) at 4°C for no more than 12 hours.
Three weeks after the cartilage biopsy, a second operation was performed.
The pigs were medicated and anesthetized as previously described. The knee
joint was approached through the previously used incision site and the initial
lesion was debrided from scar tissue. In the two treatment groups, the entire
cell amount yielded from cell expansion was used (Table 5).
In the rhCo-PLA group, approximately 40 μl of chondrocyte suspension was
pipetted into a sterile rhCo-PLA scaffold that was then implanted and sutured
to  the  adjacent  healthy  cartilage  rim.  The  rest  of  the  cell  suspension
(approximately 160 μl) was pipetted onto the scaffold for maximum cell count.
In the pCo group, protocol described by Brittberg and colleagues (Brittberg
et al. 1994) was followed, but the periosteal graft was replaced with the pCo
membrane. Cell suspension was injected under the pCo membrane and the
sutured seam was secured with fibrin glue.
The cartilage defects in the spontaneous group were debrided as described
above, but the lesions were left without treatment for spontaneous repair. The
follow-up time for each group was four months.
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Table 5. Number of autologous chondrocytes implanted in each animal.
Group Pig n:o Cells/defect
rhCo-PLA 18 15.0
21 10.5
25 5.6
26 4.6
29 14.4
31 12.6
mean 10.5
pCo 19 13.9
23 14.4
27 11.9
28 9.9
30 9.8
32 8.5
mean 11.4
spontaneous 5 0
11 0
15 0
16 0
17 0
mean 0
4.3.2 OSTEOCHONDRAL INJURY AND REPAIR WITH BONE FILLERS
(II)
All  rabbits  were operated under general  anesthesia induced with 0.5 mg/kg
(s.c.) medetomidine and 25 mg/kg (s.c.) ketamine. Preoperative analgesia of
0.05  mg/kg  (s.c.)  of  buprenorphine  and  4  mg/kg  (s.c.)  of  carprofen  was
administered.  All  the  animals  received  40  mg/kg  (i.m.) of cefuroxime
preoperatively.
The animals were set on a supine position on the operating table. A medial
parapatellar  arthrotomy  was  made  to  the  right  hind  limb.  The  patella  was
dislocated laterally, and the femoral condyles were exposed. A single lesion
through the articular cartilage of the medial condyle was made with a hand-
operated drill. The lesion covered almost the width of the femoral condyle and
the  bony  defect  comprised  a  notable  volume  of  the  entire  condyle  with  a
diameter  of  4  mm,  and  a  depth  of  8  mm.  The  lesions  were  filled  with  the
studied  biomaterial  or  left  empty  for  spontaneous  repair.  The  granular
materials BG and β-TCP were mixed with sterile water to create a paste-like
composition prior to implantation. The PLGA and PLGA-BGf samples were
semi-rigid  plugs  which  were  press-fitted  into  the  lesion.  The  incisions  were
closed  in  layers.  After  the  operation,  1  mg/kg  (s.c.) of antipamexole was
administered for reversal of the sedative effects of medetomidine.
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The animals were allowed free weight-bearing and unrestricted movement
after the operation. Antibiotic prophylaxis of 40 mg/kg (s.c.) of cefuroxime
was continued three times a day for three days and postoperative analgesia of
0.01 mg/kg (s.c.)  of  buprenorphine and 4 mg/kg (s.c.) of carprofen for four
days. The follow-up time was 12 weeks.
4.3.3 CHONDRAL AND OSTEOCHONDRAL INJURIES (III)
All the horses were assessed clinically and radiologically prior to inclusion in
the study and were found to present no abnormalities. The horses received
meloxicam pre-operatively (0.6 mg/kg, i.v., Metacam®, Boehringer
Ingelheim, Ingelheim am Rhein, Germany). Surgery was performed under
general anesthesia. The middle carpal joints were approached through a
latero-dorsal and medio-dorsal 1.5–2 cm length arthrotomy to create defects
on the 2nd,  3rd and 4th carpal  bones.  The defects  were pre-punched with a 2
mm, 4 mm, 6 mm, or 8 mm skin biopsy punch. For chondral defects, cartilage
was carefully  removed with ring curettes onto the level  of  calcified cartilage
(approximately 1 mm in depth) in the left carpus. For osteochondral lesions
created in the right carpus, drilling was performed under continuous lavage
with Ringer’s solution using a hand drill. A 2, 4, 6, or 8 mm pointed drill bit
was initially used, followed by a custom-made flattened drill bit of the same
size  and  a  custom-made  drill  sleeve  to  provide  a  uniform  defect  with  a
flattened bottom and controlled depth of 3.5 mm. Healthy cartilage adjacent
to the lesions served as control for all defects.
Postoperatively, the animals were confined to individual box-stalls
(3.5×3.5m)  for  two  weeks,  after  which  a  gradual  six-week  rehabilitation
program consisting of incremental controlled walking started. Thereafter,
depending on the season and weather conditions, the animals were turned out
to  pasture  or  kept  in  box  stalls  with  daily  exercise  in  a  mechanical  horse
walker.  The  total  follow-up  period  was  12  months  during  which  the  lesions
were allowed to heal spontaneously.
4.4 CELL CULTURES (I, IV)
4.4.1 PORCINE CHONDROCYTE ISOLATION AND MONOLAYER CELL
CULTURE (I)
A circular chondral biopsy with a diameter of 8 mm was taken with a biopsy
punch from the medial femoral condyle of a domestic pig as described above.
The cartilage biopsy was minced with a surgical blade and digested overnight
in type II collagenase (Worthington Biochemical Corp., Lakewood, NJ, USA)
in a cell culture medium comprised of Dulbecco’s Modified Eagle’s Medium
(DMEM-F12,  Gibco,  Invitrogen,  Paisley,  UK)  supplemented  with  10%  Fetal
Bovine  Serum,  1%  GlutaMAXTM (Gibco, Invitrogen), 1% Penicillin-
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Streptomycin (Gibco, Invitrogen), 1% amphotericin B and 50 μg/ml sodium L-
ascorbate  (Sigma Aldrich,  St.  Louis,  MO,  USA).  The  obtained  chondrocytes
were cultured in the above described medium until passage 2 and then stored
at -140°C.
4.4.2 HUMAN CHONDROCYTE AND MSC ISOLATION AND THREE-
DIMENSIONAL CELL CULTURES (IV)
Cartilage was harvested from a male cadaver donor. Both knees were opened
through a medial parapatellar incision and the patella was lateralized to
expose femoral condyles. Articular cartilage was harvested with a surgical
blade from both condyles and the cartilage pieces were placed in sterile PBS.
The cartilage pieces were minced and digested as described above. The
obtained chondrocytes were cultured until passage 3 in the above described
chondrocyte culture medium, where after day 0 samples were collected.
Human bone marrow-derived mesenchymal stem cells were obtained from
the Finnish Red Cross Blood Service. Bone marrow samples were drawn from
three healthy male volunteers and MSCs were isolated, characterized and
cultured in MSC proliferation medium until passage 1 before storing them in
liquid  nitrogen  in  aliquots.  The  cells  were  then  thawed  and  cultured  until
passage 2 before collecting day 0 control samples. The proliferation medium
consisted of DMEM-F12 supplemented with GlutaMAX (21885-025, Gibco,
Invitrogen),  10%  platelet  rich  plasma  (Finnish  Red  Cross  Blood  Service,
Helsinki, Finland), 1% PenStrep (Gibco, Invitrogen), and 40 IU/ml heparin
(LEO Pharma, Ballerup, Denmark).
Three  types  of  biomaterial  scaffolds  (rhCo2-PLA,  rhCo3-PLA,  pCo)  were
placed on a 24-well plate and a suspension of 0.5×106 chondrocytes or MSCs
was pipetted onto each scaffold. The cells were then cultured in chondrocyte
proliferation medium, MSC proliferation medium, or xeno-free differentiation
medium. The xeno-free chondrogenic differentiation medium for MSCs
comprised of Dulbecco’s Modified Eagle Medium (41966-029, Invitrogen)
supplemented  with  1%  PenStrep,  1.5  mg/ml  human  serum  albumin  (Sigma
Aldrich), 40 μg/ml L-proline (Sigma Aldrich), 25 μg/ml ascorbic acid (Sigma
Aldrich),  10  μg/ml  insulin  (Insuman  Rapid,  Sanofi),  8  μg/ml  human
transferrin (Sigma Aldrich), 5.5 μg/ml linoleic acid (Sigma Aldrich), 40 ng/ml
dexamethasone (Oradexon, Shering-Plough), 10 ng/ml sodium selenite
(Sigma  Aldrich),  and  10  ng/ml  TGF-β1 (R&D  Systems,  Minneapolis,  MN,
USA) (Skog et al. 2015).
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4.5 MACROSCOPIC EVALUATION (??III)
After sacrifice, the operated and contralateral non-operated knees of the pigs
(study I) and rabbits (study II), and left and right carpal joints of the horses
(study III) were dissected free and the cartilage surfaces were photographed.
In studies I and III, cylindrical osteochondral samples containing the defect
site in the middle were cut and the cylinders were stored at -20°C until further
processing. In study II, the detached lapine femurs were stored in 10%
buffered formalin at +4°C until further processing.
The porcine photographs were blinded and evaluated by four independent
observers following the ICRS Cartilage Repair Assessment System (Brittberg
& Winalski 2003).
4.6 IMAGING (??III)
4.6.1 μCT (??III)
Quantitative analyses of  the subchondral  bone in studies I─III were carried
out  with  μCT  imaging.  The  volume  of  interest  (VOI)  in  each  study  was  a
cylinder  that  was  chosen  to  cover  the  operated  area  and  underlying
subchondral  bone.  Osteochondral  plugs  in studies I─II were  scanned  with
MicroXCT-400 (Zeiss Xradia, Pleasanton, CA, USA) with unfiltered X-ray
beam,  100  kV  source.  The  cross-sectional  images  were  reconstructed  with
XMReconstructor software (version 8.1, Zeiss Xradia). The images were post-
processed and analyzed with Avizo Fire 8.1 (FEI Visualization Sciences Group,
Hillsboro, OR, USA) software and Fiji with BoneJ plugin (Doube et al. 2010,
Schindelin  et  al.  2012).  In study III, SkyScan-1172 scanner (SkyScan,
Aartselaar, Belgium) with X-ray tube voltage of 100 kV was used to analyze the
subchondral  bone.  Image  analysis  was  conducted  with  the  CT  Analyser
(version 1.10.1.0; SkyScan). The analyzed parameters in each study were bone
volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separation
(Tb.Sp), and trabecular number (Tb.N).
4.6.2 MRI (III)
In study III,  samples  were  thawed,  placed  in  a  test  tube  and  immersed  in
saline.  Magnetic  resonance  imaging  was  carried  out  with  a  9.4  T  device
(Oxford 400 NMR vertical magnet; Oxford Instruments, Witney, England),
equipped with a Varian DirectDrive console (VnmrJ 2.3, Varian, Palo Alto, CA,
USA)  and  a  19  mm  quadrature  volume  coil  (RAPID  Biomedical,  Rimpar,
Germany). T2 relaxation time was measured in a single slice of 1 mm thickness
using a single echo spin echo sequence with echo times (TEs) of 12, 24, 50, 80
and 110 ms, a repetition time (TR) of 2.5 s and in-plane resolution of 70×140
μm. Native T1 relaxation time was measured in the same slice with the same
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resolution, using a progressive saturation recovery sequence with TRs of 0.3,
0.6, 1.2, 2.4, and 4.8 s and TE of 11.7 ms. Gadolinium-enhanced T1 values (T1Gd)
were retrieved by imaging the samples after 20 hour immersion in a 1.0 mM
Gd-DTPA2- solution using TRs of 0.1, 0.2, 0.4, 0.8, and 1.6 s.
The tissue was analyzed at two regions of interest (ROIs). ROI1 covered any
repair  tissue at  the lesion sites.  ROI2 was aligned with the adjacent healthy
cartilage and split into superficial and deep halves. A control ROI at the site of
healthy tissue was also split into superficial and deep halves.
4.7 MECHANICAL TESTING (I)
Osteochondral samples of the porcine knees were thawed and their cartilage
thickness at the defect site was measured with ultrasound imaging (Clear View
Ultra, Boston Scientific). Indentation technique was used for biomechanical
testing. The testing was carried out in a chamber filled with PBS containing
metalloprotease inhibitors 5 mM EDTA (ethylenediamide tetraacetic acid
disodium  salt,  VWR  International  LCC,  Fontenay,  France)  and  5  mM
benzamidine hydrochloride (Sigma-Aldrich) (PBSI). A cylindrical plane-
ended indenter (diameter 610 μm) was brought into contact with the cartilage
surface at the site of the cartilage thickness measurement. Stepwise stress-
relaxation tests (four steps, compression of 5% of cartilage thickness each, 0.1
mm/s ramp rate, 30 minutes relaxation between each step) were performed.
A fibril reinforced poroelastic finite element cartilage model was constructed
with Abaqus (V6.12-3, Dassault Systèmes Simulia Corp, Providence, RI, USA)
to characterize the mechanical parameters of the repair tissue. In this model,
collagen  fibrils  are  modeled  as  nonlinear  springs  and  biphasic
porohyperelastic non-fibrillar matrices represent porous proteoglycan
structure filled with fluid. Material parameters (non-fibrillar matrix modulus
Em,  collagen fibril network modulus Ef, and permeability k0) of the articular
cartilage samples were optimized by minimizing the mean absolute error of
the second stress-relaxation step between the simulations and experimental
stress-relaxation data with Matlab software (V7.14.0, Mathworks Inc, USA).
Other parameters in the model were kept constant.
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4.8 MICROSCOPIC METHODS (??IV)
4.8.1 TISSUE SECTIONS (??IV)
4.8.1.1 Paraffinized sections (I, III, IV)
Osteochondral sample cylinders (studies I and III) and cell pellets (study IV)
were fixed in 0.1M phosphate-buffered 10% formalin at room temperature
(RT). The samples were decalcified in 10% EDTA and 4% formaldehyde in 0.1
M phosphate buffer at RT, then cut in half, dehydrated in ascending alcohol
series and cleared with xylene before embedding in paraffin.
4.8.1.2 Hard tissue sections (II)
The formalin-fixed rabbit femurs were carefully split into two using a jig saw.
The samples were dehydrated in ethanol, cleared with xylene immersions and
subsequently embedded in methyl methacrylate.
4.8.2 STAININGS (??IV)
For studies I, III and IV,  the 5 μm thick tissue sections were deparaffinized
with xylene and rehydrated in descending alcohol series. The sections were
incubated  in  0.5%  Safranin-O  (in  0.1M  acetate  buffer,  pH  4.6)  and
subsequently washed in running water for 10 minutes.
In study II, the hardened tissue blocks were cut into 5─10 μm thick sections
with a Leica SM 2500 hard tissue slide microtome and stained with Masson’s
Goldner trichrome.
4.8.3 HISTOLOGICAL SCORING OF REPAIR TISSUE (I, III)
In study I,  the  Safranin-O  stained  tissue  sections  were  evaluated  by  two
blinded, independent observers according to ICRS Histological Visual
Assessment Scale (Mainil-Varlet et al. 2003). The score evaluates the repair
tissue surface, matrix, cell distribution, cell viability, subchondral bone, and
cartilage mineralization. Normal hyaline cartilage receives an overall score of
18.
The Safranin-O stained tissue sections in study III were evaluated using the
OARSI  equine  histopathology  score  (McIlwraith  et  al.  2010).  The  sections
were scored by three independent, blinded observers. The defects that lacked
any repair tissue were given the worst total score of 20.
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4.8.4 HISTOMORPHOMETRY (II)
The stained sections were imaged with Olympus BX-60 microscope with an
integrated  Scion  color  digital  camera.  The  qualitative  assessment  of  the
amount of osteoid and lymphocytes was carried out with the naked eye. The
specimens  were  classified  according  to  the  number  of  lymphocytes  and
macrophages into having 0─50 cells, 50─100 cells, 100─500 cells, or over 500
cells  per  tissue  slide.   Due  to  the  low  quantity  of  osteoid  in  the  samples,
quantitative assessment of the amount of osteoid could not be made.
4.8.5 IMMUNOHISTOCHEMISTRY (I, III, IV)
The  5  μm  thick  tissue  sections  were  digested  in  hyaluronidase  (2  mg/ml,
Sigma-Aldrich)  and  pronase  (2  mg/ml,  Calbiochem,  Merck  KGaA).  The
sections were treated with 0.03% hydrogen peroxide (EnVision®+ System-
HRP  (AEC),  Dako  North  America  Inc.)  to  block  endogenous  peroxidase
activity  and  with  10%  normal  goat  serum  (Dako  Denmark  A/S,  Glostrup,
Denmark)  to  block  non-specific  staining.  The  sections  were  then  incubated
overnight at  4°C with primary antibodies against  collagen type II  (ab34712,
Abcam)  and  collagen  type  I  (ab34710),  and  diluted  to  4  μg/ml  with  PBS
supplemented  with  1%  bovine  serum  albumin  (Sigma-Aldrich)  and  0.1%
Triton X-100 (Sigma-Aldrich). Negative controls were incubated with rabbit
immunoglobulin. Horseradish peroxidase (HRP)-conjugated goat anti-rabbit
secondary antibody (Dako) was subsequently applied on the slides. Antibody
binding was visualized with AEC (3-amino-9-ethylcarbazole) substrate
chromogen (Dako).
4.8.6 POLARIZED LIGHT MICROSCOPY (III)
Polarized light microscopy (PLM) describes cartilage structure and collagen
fibril  network.  Unstained  5  μm  thick  tissue  sections  were  imaged  using
polarized light microscopy (Leitz Ortholux II POL, Leitz Wezlar, Wezlar,
Germany) as described by Rieppo (Rieppo et al. 2008). The repair tissue was
evaluated  using  a  300-μm-wide  ROI,  which  was  divided  into  ten  layers  of
equal thicknesses for the analysis. The orientation of collagen fibrils in relation
to  the  cartilage  surface  (0–90  degrees),  and  parallelism  index  (PI),  which
describes the randomness of fibril orientations within the pixel (0─1, where 0
indicates completely random organization and 1 indicates completely parallel
organization),  were  determined  from  the  most  superficial,  middle  and  the
deepest layer.
4.8.7 CONFOCAL MICROSCOPY (IV)
The cells in the scaffolds were fixed with 10% buffered formalin and stained
with Hoechst (Invitrogen). The cell nuclei were then imaged with a fluorescent
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confocal microscope Leica TC SP8 CARS (Leica Microsystems) with 25× HCX
IR APO L water objective and Leica Application Suite Advanced Fluorescence
software (version 3.3.0.10134). For each sample, three fields of view from the
most representative areas were imaged and a maximum projection image was
created with a mean stack size of 320 μm.
4.9 BIOCHEMICAL METHODS (IV)
4.9.1 RNA EXTRACTION
To obtain the nucleic acids from each sample, the cell–scaffold constructs were
mechanically disrupted using Tissue Lyser II (Qiagen, Hilden, Germany) with
carbide beads. The samples were homogenized with QIAzol® Lysis Reagent
(Qiagen Sciences, Maryland, USA, cat. no. 79306) and the RNA was separated
from  the  organic  phase  with  chloroform  (Sigma-Aldrich).  RNeasy  Mini  Kit
(Qiagen) was used to further purify the samples.  Total  RNA yield and RNA
purity were measured with NanoDrop 1000 spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). The RNA samples with 260/280 values <1.6
and 260/230 values <0.1 were omitted from the final analyses.
4.9.2 CDNA SYNTHESIS
Reverse transcription of RNA to single-stranded cDNA was carried out in PCR
tubes (Nippon Genetics Europe GmbH, Dueren, Germany) using a commercial
kit (High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor;
Applied  Biosystems,  Foster  City,  CA,  USA)  according  to  the  manufacturer’s
instructions.  The  RNA  amount  used  in  the  reactions  was  100  ng  for  each
sample.  The reverse transcription program was as follows:  25°C for 10 min,
37°C for 120 min, 85°C for 5 minutes. The resulted cDNA was stored in -20°C.
4.9.3 QPCR
The expression levels were measured for chondrogenic genes SOX9, COL2A1,
ACAN; for osteogenic markers RUNX2 and COL10A1; and for synovial
fibroblast marker MFAP5 using  a  commercial  gene  expression  assay
(TaqMan® Gene Expression Assay, Applied Biosystems; Table 6). The real-
time  qPCR  analysis  was  performed  with  iQTM5  Multicolor  Real-Time  PCR
Detection  System  (Bio-Rad  Laboratories,  Hercules,  CA,  USA).  The
amplification reaction conditions were as follows: Hold in 50°C for 2 minutes,
hold in 95°C for 10 minutes, cycle 95°C for 15 seconds and 60°C for 1 minute
repeated 40 times. The gene expression levels were normalized to GAPDH and
day 0 samples in the ΔΔCT method (Livak & Schmittgen 2001).
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Table 6. Gene expression assays used in study IV.
Gene Full name TaqMan code
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1
ACAN Aggrecan Hs00153936_m1
COL2A1 Collagen, type II, alpha 1 Hs00264051_m1
COL10A1 Collagen, type X, alpha 1 Hs00166657_m1
MFAP5 Microfibrillar Associated Protein 5 Hs00185803_m1
RUNX2 Runt-related transcription factor 2 Hs00231692_m1
SOX9 SRY (sex determining region Y)-box 9 Hs00165814_m1
4.9.4 SGAG/DNA
The amount of sulfated glycosaminoglycans in each cell-scaffold-construct
was analyzed using the dimetyhylmethylene blue-based (DMMB) assay. The
scaffold─cell contstructs were washed twice with PBS, placed dry in Eppendorf
tubes and stored immediately at -80°C. The samples were digested in 1 mg/ml
Proteinase K (Sigma-Aldrich) in PBS at  +60°C overnight.  Subsequently,  the
samples  were  centrifuged  at  10  000  g  for  10  min  and  the  supernatant  was
collected for the measurements. The sGAG amount was quantified using
Blyscan assay (Biocolor, UK) according to the manufacurer’s protocol. Briefly,
100  μl  of  sample  supernatant  was  mixed  with  1  ml  of  Blyscan  reagent  and
incubated in gentle shaking for 30 min. The samples were centrifuged at 8 000
g for 10 min and supernatant was discarded. Precipitated sGAG pellets were
dissolved  with  0.5  ml  of  dissociation  reagent  and  vortexing.  Samples  were
transferred t a 96-well plate in duplicates, and the absorbance was measured
with a microplate reader at 656 nm. To normalize the sGAG amount to DNA
content, PicoGreen assay (Molecular Probes, Invitrogen) was used according
to the manufacturer’s instructions. The samples were diluted 1:10 and 50 μl of
the dilutions was transferred to a 96-well plate in duplicates. Subsequently, 50
μl of PicoGreen working solution was added to each sample and incubated for
2─5 min  at  RT.  The  fluorescence  of  DNA  was  measured  with  a  microplate
reader at 480/520 nm.
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4.10 STATISTICAL ANALYSES (??IV)
The data in studies I–IV are presented as mean±standard error (SE), unless
otherwise specified. A p value under 0.05 was used as the threshold to indicate
a statistically significant difference in each study.
4.10.1 STUDY I
Relative differences between the operated and the non-operated contralateral
knees were calculated and the differences in the relative values were revealed
by one-way analysis of variance (ANOVA) testing and Kruskall-Wallis testing
with exact p values. Differences between the operated knees of each group
were calculated with permutation ANOVA. Correlation analysis for cell count
and histological score was carried out with Spearman’s correlation test.
4.10.2 STUDY II
Each parameter for operated knees was compared with the corresponding
non-operated control to calculate relative μCT values. The relative values were
used to compare the groups with each other. Statistical analyses were carried
out using the permutation type ANOVA test with Holm adjustment.
4.10.3 STUDY III
Osteochondral and chondral lesions of the same diameter were compared to
each other. The significances of differences in the μCT, MRI and polarized light
microscopy parameters were evaluated with a pairwise t-test, and Sidak
adjustment was made for multiple testing. Significances of difference in lesion
filling was calculated with repeated ANOVA testing and Sidak adjustment.
4.10.4 STUDY IV
Differences between scaffolds were determined with permutation type
ANOVA. In cases of p<0.05, it was followed by pairwise multiple comparisons
with the Bonferroni procedure.
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4.11 ETHICAL CONSIDERATIONS
Studies I─III involved  the  use  of  experimental  animals.  Although  Russel’s
principal of 3R’s encourage to replace animal models with methods of other
kinds, articular cartilage repair in weight-bearing conditions cannot be
investigated without the use of animal models. Studies I─II were conducted
according  to  the  ethical  guidelines  and  regulations  of  the  Finnish  Act  on
Animal Experimentation (62/2006). Studies I─II were  authorized  by  the
Finnish National Animal Experiment Board (ESAVI-3146/04.10.03/2011 and
ESAVI-3785/04.10.03/2011) prior to the commencement of the studies. Study
III was authorized by the Utrecht University Animal Experiments Committee
(0412.0601)  in  compliance  with  the  Dutch  Act  on  Animal  Experimentation
and the animal care was in accordance with Utrecht University guidelines.
The use of cadaveric chondrocytes and human mesenchymal stem cells in
Study IV were approved by Ethics Committee, Department of Surgery of the
Helsinki University Hospital (7/13/03/02/2014), and an informed consent
was received in written form from all volunteer bone marrow donors.
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5 RESULTS
5.1 SURGICAL PROCEDURES AND ANIMAL
WELLBEING (I–III)
In study I,  one  animal  from  the  spontaneous  group  and  one  from  the  pCo
group developed a severe wound infection after the repair operation and were
prematurely euthanized. In study II, three animals (one from groups PLGA, β-
TCP and spontaneous, each) died during the induction of anesthesia, probably
due  to  respiratory  arrest  caused  by  the  combination  of  ketamine  and
medetomidine (Calasans-Maia et al. 2009). Otherwise, surgeries in studies
I─III were carried out without complications and the animals recovered well
and no clinical abnormalities were detected.
5.2 MACROSCOPIC EVALUATION OF REPAIR TISSUE
(I–III)
Modest synovial fluid excess and inflammation of synovial tissue was observed
in two pigs (one from group rhCo-PLA and one from group pCo) at the time of
the sacrifice. Otherwise, no synovitis or degenerative changes were observed
in any of  the operated knees.  According to the ICRS consensus score,  ≥75%
filling of the defects was observed in 2/5 specimens in spontaneous group, 3/6
in rhCo-PLA group and 3/6 in pCo group, respectively. The mean macroscopic
ICRS score  was  highest  in  spontaneous  group  (7.0±1.5)  compared  to  rhCo-
PLA  treatment  (5.3±2.0)  and  pCo  treatment  group  (6.8±1.6)  but  the
differences were not statistically significant (p=0.75).
In study II,  all  groups  showed  good  macroscopic  lesion  filling  up  to  the
cartilage surface.  The surface of  the repair  tissue in the defect  areas in each
group was  uneven  and  differed  by  color  from healthy  cartilage  but  no  deep
tissue deficiencies or degenerative changes around the defect areas or in the
articulating surfaces were detected.
In study III,  the 2 mm chondral  lesions showed good macroscopic filling
(Figure 3). The 4 mm and 8 mm chondral lesions were clearly distinguishable
from the surrounding healthy cartilage and were incompletely filled (Figure
3). Lesion filling was better in the osteochondral lesions in which the repair
tissue reached the level of the surrounding cartilage surface in all of the 2 mm
lesions (Figure 3). The overall filling of osteochondral samples did not differ
from healthy control cartilage (p=0.085), whereas the filling of the 4 mm and
8 mm chondral samples was decreased in comparison to controls (p<0.001).
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Figure 3 Filling of the chondral and osteochondral defects in study III. The top and bottom
of each box represent the first and third quartiles, the horizontal line inside the
box is the median, and the whiskers are the 10th and 90th percentiles. The circles
are outliers.
5.3 VISUAL APPEARANCE OF BONE STRUCTURE IN
μCT IMAGING (I–III)
In study I, subchondral bone voids in the pigs were greater in the treatment
groups  than  in  the  spontaneously  healed  group  (Figure  4),  although  no
statistically significant differences were found between the study groups
(p=0.24). Mean void volumes for rhCo-pPLA, pCo and spontaneous groups
were 53.1±18.6 mm3, 50.0±10.2 mm3 and 21.1±7.6 mm3, respectively.
Subchondral bone voids were more common in the pCo-treated group (6/6)
than  in  the  rhCo-PLA-treated  group  (3/6)  or  the  untreated  control  group
(2/5).
Figure 4 μCT image of the largest and smallest bone void in each study group in study I.
Scale bars 2 mm.
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In the lapine study, no signs of granular biomaterial detachment from the
defect areas or bone cysts were observed. PLGA rods resulted in variable defect
filling  with  partial  bony  repair  which  migrated  from  the  defect  periphery
towards the middle of the defect. The bone–cartilage interface showed an
uneven mineral surface. One defect in the PLGA group and all defects filled
with PLGA-BGf appeared empty in visual evaluation of μCT images.
The granular commercial controls β-TCP and BG resulted in repair tissue
that was visually slightly depressed on the surface, under which the mineral
structure appeared very dense (Figure 5). One BG-filled specimen showed an
empty void in the middle of the original burr canal in an otherwise well filled
defect (Figure 5b). Unresolved β-TCP and BG were clearly distinguishable in
the μCT images.
For spontaneously healed control defects, it was typical that there was a
slight depression of  the joint  interface (Figure 5c).  The defects  in the group
were variably healed,  either with good filling,  a  layer of  dense bone with an
empty  defect  underneath  or  repair  tissue  with  a  non-healed  shaft  in  the
middle. Canal-like voids extending from the joint surface towards the marrow
spaces were seen in 3/7 specimens.
Figure 5 a) Unresolved granular biomaterials were clearly visible in defect areas. ?-TCP
was visually distinguishable from the bone by its clearer white color. b) The
asterisks mark the unreacted BG granules and arrows show the darker gray
area of silica gel layer onto which hydroxyapatite crystallizes. c) Spontaneously
healed defects showed a depression near the surface.
In the equine study, bone structure was normal under the 2 mm and 4 mm
chondral lesions in visual observation of the μCT images. Subchondral bone
showed signs of decreased compactness in 4/5 large 8 mm chondral lesions
and one of these samples showed a small bone cyst underneath the chondral
defect.  By  contrast,  subchondral  bone  changes  were  observed  in  14/15
osteochondral defects. Only two osteochondral samples with a diameter of 2
mm presented without bone cysts. All osteochondral lesions of 4 mm and 8
mm in diameter had unhealed bone or a cystic bone lesion.
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5.4 BONE STRUCTURAL PARAMETERS (I–III)
BV/TV and Tb.Th in the operated porcine femurs were slightly increased in
comparison  to  non-operated  contralateral  control  knees  (Table  7)  but  the
different study groups did not differ from one another with respect to any of
the studied parameters.
In the lapine study, trabeculae were thin and densely located in both the β-
TCP  and  BG  groups,  whereas  trabeculae  in  the  spontaneously  healed  and
PLGA  groups  were  thick  and  sparse.  The  β-TCP-treated  knees  showed  the
highest  relative bone volume fraction when compared with all  other groups
(p<0.001).
In  the  equine  study,  variation  between  individual  horses  and  individual
samples  was  large,  leading  to  no  statistically  significant  changes  in  the
subchondral bone trabecular parameters.
Table 7. The structural bone parameters in each study group and controls. All values are
presented as mean±SE. BV/TV, bone volume fraction; Tb.Th, trabecular
thickness; Tb.Sp, trabecular separation; Tb.N, trabecular number.
BV/TV (%) Tb.Th (μm) Tb.Sp (μm) Tb.N (μm-1)
Porcine femur, chondral defects
 rhCo-PLA 54.5±2.9 211.3±9.8 273.0±30.6 2.1±0.1
pCo 54.1±2.8 205.2±10.0 253.2±15.5 2.2±0.1
  spontaneous 54.8±3.1 217.4±9.0 284.0±12.5 2.0±0.0
  healthya 49.1±1.2 183.4±4.6 287.3±5.0 2.1±0.0
Lapine femur, osteochondral defects
 PLGA 33.6±1.4 354.3±19.0 1050.1±121.5 0.7±0.1
PLGA-BGf 25.1±3.6 295.5±17.7 1983.7±178.0 0.5±0.0
?-TCP 46.0±1.3 225.5±9.5 528.6±26.1 1.3±0.0
  BG 30.5±1.7 161.1±8.6 631.8±48.5 1.3±0.1
  spontaneous 37.1±1.6 364.1±29.5 1143.8±95.9 0.7±0.1
  healthya 33.6±0.6 250.0±6.3 611.5±14.6 1.2±0.0
Equine carpus, chondral defects
 2 mm 44.2±13.4 84.8±12.5 149.7±23.2 4.6±1.0
4 mm 47.3±8.3 89.9±8.5 131.3±8.5 5.1±0.7
  8 mm 46.6±10.3 89.9±8.1 141.6±12.8 5.0±0.8
 healthyb 31.7±9.1 85.3±10.1 227.5±36.2 3.4±0.8
Equine carpus, osteochondral defects
  2 mm 45.7±8.3 93.1±3.2 120.8±11.8 4.8±0.7
  4 mm 33.5±4.9 87.5±3.1 158.2±11.3 3.8±0.5
  8 mm 48.9±4.4 94.6±1.4 141.9±10.3 5.2±0.4
  healthyb 43.5±3.2 103.5±2.2 180.7±11.4 4.2±0.2
a contralateral non-operated knees. b tissue adjacent to the defect sites in carpus
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5.5 MR IMAGING OF EQUINE REPAIR TISSUE (III)
Repair tissue in the defects showed a trend of shorter T1Gd relaxation times and
longer T1 relaxation  times  than  control  tissue  (Figure  6).  Osteochondral
defects had longer T1Gd relaxation times than the chondral defects, although
the differences were not statistically significant. The T2 relaxation time was
shorter in the 8 mm osteochondral lesions than in chondral lesions with the
same diameter  in  ROI1  (repair  tissue  only)  (33.8±0.8  ms  and  41.0±1.3  ms,
respectively; p=0.017) and deep part of ROI2 (lesion area aligned to adjacent
healthy cartilage) (48.9±8.4 ms and 103.9±12.2 ms, respectively; p=0.020).
There were no statistically significant differences in T1 relaxation times
between the groups. In ROI2, there was a trend of increasing T1 relaxation time
with  lesion  diameter  and  towards  the  cartilage  surface  in  the  chondral
samples, an implication of increasing water content and structural
disorganization (Figure 6).
Figure 6 Boxplot graphs showing the results of the MRI analyses. The top and bottom of
each box represent the first and third quartiles, the horizontal line inside the box
is the median, and the whiskers are the 10th and 90th percentiles. The circles are
outliers. All statistically significant p values are marked in the figure.
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5.6 HISTOLOGICAL EVALUATION OF REPAIR TISSUE
(I–III)
Visualization of proteoglycans with Safranin-O staining demonstrated that the
repair tissue had abundant proteoglycan content in all porcine study groups
(Figure  7).  In  one  of  the  two  collapsed  rhCo-PLA samples,  the  scaffold  was
detached since no polylactide fibers could be detected in the histological
sections. In the other one, the scaffold was sunken into the subchondral bone.
When the  rhCo-PLA scaffold  was  well  aligned  with  the  native  cartilage,  the
integration  was  good  with  no  borderline  between  native  and  repair  tissue
(Figure  7).  The  pCo  treatment  group  and  the  spontaneously  healed  group
showed lesion perimeter collapse and grainy lesion borders in the majority of
the samples.
Figure 7 Representative image showing the repair tissue in an rhCo-PLA-treated defect.
a) Safranin-O staining showed abundant proteoglycans throughout the repair
tissue area. Polylactide fibers appeared as white dots and rods within the
cartilage tissue. b) Immunohistochemical staining for type I collagen showed
that the stain was mostly on the surface of the cartilage tissue. c)
Immunohistochemical staining for type II collagen showed abundant type II
collagen throughout the repair tissue. Air bubble artefact appears as gray areas
on the slide. d) Magnification of the type II collagen stain showed the pericellular
distribution of the stain. Scale bars: a-c: 500 μm, d: 50 μm.
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The total ICRS Visual Histological Assessment Scale score (mean±SE) for
rhCo-PLA group was 11.8±1.9, for pCo group 8.5±2.7 and for spontaneous
group 9.6±1.5 (p=0.43). Variation between individual animals was large
(Figure 8a).
The OARSI histological score showed worse score in all of the equine lesions
compared to the control tissue (Salonius et al. unpublished data). Dispersion
of the results was large especially in the 4 mm and 8 mm chondral lesions, as
depicted in Figure 8b.
Figure 8 a) The total histological ICRS score (0–20, where 0 represents healthy cartilage)
in study I. No statistically significant differences were found between the study
groups. b) The OARSI score (0–20 where 20 represents healthy cartilage) in
study III. All p values for comparison of each study group with adjacent healthy
control tissue are marked in the figure. Only chondral defects with a diameter of
2 mm did not differ from healthy control tissue. The dark line in the middle of the
boxes represents the median value. The bottom of the box indicates the first
quartile and the top of the box indicatesthe third quartile. The whiskers represent
the 10th and 90th percentiles.
In study III, only 1/15 chondral lesions showed Safranin-O positivity in the
histological sections, whereas 11/15 of osteochondral defects stained positively
for  Safranin-O.  Typically,  the  osteochondral  samples  showed  mixture  of
hyaline-like and fibrous cartilage in the deep or middle part of the repair tissue
and fibrous tissue on the surface (Figure 9).
In the histological evaluation of the bone defects in the lapine model (study
II), PLGA and spontaneous group were filled with a mixture of fibrous tissue
and mineralized bone. In the PLGA-BGf group, the bone defects were filled
with fibrous tissue only. The areas that appear empty in μCT images consisted
of connective tissue and bone marrow (Figure 10). Osteoid was most abundant
in the β-TCP group where it encircled numerous small islands of mineralized
bone.  Both  commercial  controls  showed  comprehensive  lesion  filling  with
tissue where mineralized bone and osteoid alternated with cell-rich fibrous
tissue.  Although  the  bone  defect  filling  was  good,  there  was  a  connective
tissue-filled depression of the joint interface in the β-TCP and BG groups.
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Figure 9 Examples of Safranin-O and type I and II collagen stainings of 8 mm defects in
the equine model. The left panel shows a representative osteochondral defect
and the right panel shows a representative chondral defect. Scale bars: 1 mm.
Figure 10 Masson-Goldner trichrome stained sections showing the tissue structure of the
defect area in each group. Scale bar a-e: 1 mm. a) PLGA; b) PLGA; c) PLGA-
BGf; d) ?-TCP; e) BG, f) Micro-CT image showing the unhealed defect area in
a representative PLGA-BGf specimen.
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The  overall  number  of  lymphocytes  and  macrophages  in  the  histological
sections was low. The semi-quantitative evaluation of the inflammatory cells
showed  that  3/7  specimens  in  PLGA  group  and  2/7  in  PLGA-BGf  group
showed  50─100  inflammatory  cells  on  the  slide.  No  other  group  presented
with an increase in the number of lymphocytes or macrophages.
Histological evaluation of chondral repair in study I and study III showed
that the repair tissue seemed to originate from the bone marrow spaces (Figure
9). Lack of bone marrow connection resulted in fibrous repair tissue both in
the spontaneously healed porcine and equine samples and in the ACI-repaired
porcine samples.
5.7 IMMUNOHISTOCHEMICAL EVALUATION OF REPAIR
TISSUE (I, III)
Type  II  collagen  was  evenly  and  pericellularily  distributed  throughout  the
rhCo-PLA-treated specimens, whereas the pCo-treated specimens showed
type II collagen in the peripheral rim of the repair cartilage (Figure 7). Type I
collagen was only present in the superficial  part  of  the cartilage in all  study
groups (Figure 7). All groups showed repair tissue which was predominantly
positive for type II collagen and negative for type I collagen staining (Table 8).
One specimen from the spontaneously healed group showed detachment of
repair tissue.
Almost all of the spontaneously healed equine osteochondral samples with
the diameter of 2 mm showed positive type II collagen staining and only one
of these samples showed positive type I collagen staining (Table 8). In the 2
mm chondral  samples,  positive  staining  for  type  II  and  type  I  collagen  was
shown  in  1/5  and  4/5  samples,  respectively.  Fibrocartilage  formation  was
evident in the larger chondral and osteochondral lesions where a mixture of
type I and type II collagen positive tissue was present (Figure 9). Poor quality
of the repair tissue affected the evaluation of the specimens. Two of the 4 mm
and four of the 8 mm chondral specimens were lacking any repair tissue and
were thus perceived negative for staining.
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Table 8. Number of samples in each study group with positive staining for type I or II
collagen. Detached tissue was perceived negative for staining.
type I collagen type II collagen
porcine 8 mm
 rhCo-PLA 2/6 5/6
 pCo 1/6 5/6
 spontaneous 1/5a 4/5a
equine 2 mm
chondral 4/5 1/5
osteochondral 1/5 4/5
equine 4 mm
chondral 2/5b 0/5b
osteochondral 2/5 2/5
equine 8 mm
chondral 1/5c 0/5c
osteochondral 2/5 3/5
a repair tissue detached from one spontaneously healed specimen; b repair tissue detached from two of the 4 mm
chondral specimens; c repair tissue detached from four of the 8 mm chondral specimens
5.8 BIOMECHANICAL EVALUATION OF REPAIR TISSUE
(I)
The non-fibrillar matrix modulus (Em), indicative of proteoglycan content, was
the highest in the rhCo-PLA-treated group and the lowest in the untreated
group (Figure 11). No statistically significant differences were found between
the groups (p=0.20).
Collagen fibril network modulus (Ef)  and  permeability  (k0)  showed  no
statistically significant differences between the study groups (p=0.18 and
p=0.14, respectively). The permeability of the contralateral non-operated
knees in the untreated group was greatly increased compared to the treatment
groups, indicating worsened tissue quality (Figure 11).
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Figure 11 Biomechanical testing of the operated and contralateral non-operated articular
cartilage showed no statistically significant differences between the study
groups.
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5.9 COLLAGEN FIBRIL NETWORK ORGANIZATION OF
EQUINE REPAIR TISSUE (III)
PI  was  high  in  all  samples.  PI  was  higher  in  chondral  lesions  than  in
osteochondral lesions, although this difference was statistically significant
only in 2 mm lesions in the deep part of the repair tissue in which the PI was
0.89±0.02 for chondral and 0.79±0.03 for osteochondral defects (p=0.042).
Collagen fibril orientation showed large variation between the groups and
between individual samples. Collagen orientation changed toward the typical
tangential  orientation  in  the  superficial  part  of  the  2  mm  lesions.
Osteochondral  lesions  showed  a  higher  level  of  collagen  fibril  organization
compared  to  the  chondral  lesions  in  the  deep  part  of  the  tissue:  In  4  mm
defects, the orientation was 61.6±4.3° for osteochondral and 35.4±7.0° for
chondral defects (p=0.047) and in 8 mm defects, 69.5±2.7° for osteochondral
and 33.6±2.2° for chondral defects, respectively (p=0.004).
5.10 GENE EXPRESSION ANALYSES OF IN VITRO STUDY
(IV)
Only chondrogenically differentiated MSCs showed upregulation of studied
genes; chondrocytes and proliferated MSCs showed no upregulation of any of
the  studied  genes  at  any  time  point.  The  chondrogenic  gene SOX9 was  not
upregulated in any of the studied samples.
The chondrogenic gene ACAN was  slightly  upregulated  in  the  MSC-C
samples cultured in the pCo on day 14 and with a slight increase on day 28
(1.29±0.15 and 3.88±0.81 fold, respectively). In other samples, the expression
of ACAN was decreased from day 0 or even absent. The cartilage gene COL2A1
was transiently upregulated in the chondrogenically differentiated stem cells
on pCo membrane on day 14 (Figure 12); otherwise, no expression of COL2A1
was detected.
The chondrocyte hypertrophy and osteogenesis marker genes, RUNX2 and
COL10A1,  were  only  upregulated  in  the  MSC-C  samples  (Figure  12).  The
expression of RUNX2 was noted in rhCo3-PLA and pCo scaffolds on day 14
(3.49±0.52  and  3.53±0.29  fold,  respectively),  whereas  in  the  rhCo-PLA
scaffold it was absent. On day 28, the expression level of RUNX2 was highest
in pCo (6.55±0.84 fold; p<0.001) but in rhCo3-PLA it had returned close to
the level of day 0 controls (1.63±0.15). MSC-Cs seeded on the pCo membrane
showed upregulation of COL10A1 on  day  14  (29.64±4.81  fold)  and  the
expression level remained high on day 28 (20.32±5.15 fold).
Only  MSC-Cs  showed  upregulation  of  the  fibroblast/synovial  marker
MFAP5 on day 14. The expression level was highest in the rhCo-PLA scaffold,
which showed a statistically significant difference to pCo scaffold (p=0.011).
Other cell types or time points showed no upregulation of MFAP5.
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5.11 SULFATED GLYCOSAMINOGLYCANS (IV)
The highest sGAG content was found in the MSC-Ps and the lowest in the ACs.
When comparing the different scaffold types, pCo membrane showed the
highest glycosaminoglycan content in undifferentiated MSCs (p<0.001) and
lowest in the chondrogenically differentiated stem cells (MSC-C) (p<0.005) at
both time points. No statistically significant differences were found between
the different types of rhCo-PLA scaffolds.
5.12 CELL DISTRIBUTION ON THE SCAFFOLDS (IV)
Confocal imaging of the specimens demonstrated the polarity of the pCo
membrane:  the  cells  resided  in  a  sheet-like  manner  on  one  side  of  the
membrane. The cells residing in the rhCo-PLA scaffolds were distributed more
evenly at the entire depth of the scaffold. The imaging showed that there was
a good amount of cells in all scaffolds and all cell types.
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6 DISCUSSION
Cartilage defects have posed a vast challenge for surgeons for centuries
(Hunter 1743). Despite rigorous development of new treatment strategies,
healthy articular cartilage with its zonal architecture still cannot be produced.
The studies presented in this thesis improved current translational approaches
by defining the critical defect size in the equine carpus and by introducing new
biomaterials to cartilage repair. These studies evaluated surgical cartilage
repair with a broad perspective. The feasibility of several novel biomaterials,
both  for  chondral  and  osteochondral  defects,  was  studied.  Both in vitro
evaluation  of  biomaterials  in  cell  culture  and in vivo studies assessing
spontaneous and augmented repair in different animal models were covered.
The novel composite scaffold rhCo-PLA was evaluated both in vitro and in
vivo, following the roadmap of translation from bench to bedside.
6.1 TRANSLATION OF NEW TECHNIQUES: IN VITRO
STUDY
Translation of new techniques usually starts with choosing the best possible in
vitro model to investigate clinically meaningful aspects of the new approach
in controlled surroundings. For example, cellular responses to biomaterials
can be evaluated in vitro. Study IV formed a large entity, in which the fate of
different cell types in three different biomaterials were studied at several time
points in vitro.  Although bovine  chondrocytes  are  used  in  many  laboratory
studies, future clinical use of the studied materials takes advantage of human
cells. Human mesenchymal stem cells and human cadaveric chondrocytes
were used in the in vitro study of the scaffold material rhCo-PLA. All cells used
in the study were derived from young donors for the best possible regeneration
potential. The xeno-free chondrogenic differentiation medium used in the
study would allow for a cell-scaffold combination completely free of animal-
derived products.
When assessing the differences of rhCo-PLA and pCo, the latter showed a
sheet-like cell  distribution on one side of  the membrane whereas rhCo-PLA
scaffold  showed  a  more  even  cell  distribution.  There  were  slightly  more
hypertropic cells growing on pCo membrane than in rhCo-PLA. This might be
due  to  the  monolayer-like  structure  of  the  pCo  in  comparison  to  the  three-
dimensional structure of the rhCo-PLA scaffold (Caron et al. 2012). However,
cell type and cell culture medium showed a larger impact on the cell fate than
the scaffold type.
Differentiating human BM-MSCs in chondrogenic differentiation medium
and in scaffolds intended for cartilage repair resulted in increased expression
of osteogenic pathway markers. The cells also showed a transiet upregulation
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of fibroblast marker MFAP5, showing the multilineage differentiation
potential of these cells. BM-MSCs as a cell source might have a predefined fate
of endochondral ossification (Vinardell et al. 2012, Somoza et al. 2014)
although chondrogenic differentiation in pellet culture has been successful in
this study and previously (Skog et al. 2015).
Poor yield of cadaveric chondrocytes in study  IV required multiple
passaging of the cells. The passage 3 cadaveric chondrocytes did not express
any of the studied chondrogenic genes, nor did they produce extracellular
matrix with sulfated glycosaminoglycans in scaffolds. This finding indicates
that these cells have undergone dedifferentiation at an early phase of cell
culturing, and that the three-dimensional environment of rhCo-PLA scaffolds
and collagen  membrane  was  not  sufficient  for  reversing  this  change.  It  has
been known for decades that long monolayer culturing of chondrocytes causes
their dedifferentiation (Benya et al. 1978). The dedifferentiation process starts
already on day 2 of the culture as the cells start to synthetize type I collagen
but the transition extends through several weeks (von et al. 1977).
Nevertheless, passage 3 chondrocytes have been reported to produce good
quality cartilage repair tissue in a clinical setting in MACI® (Vericel
Corporation, USA), which has an FDA approval (Corbett et al. 2017, US Food
and Drug Adminstration 2016). This emphasizes the fact that the ability of in
vitro testing  to  predict  clinical  repair  responses  is  limited.  The  entire  joint
environment with its mechanical stresses, synovial fluid and underlying bone
affect cartilage restoration. Animal models are used in closing the gap between
in vitro testing and clinical studies.
6.2 SPONTANEOUS ARTICULAR CARTILAGE REPAIR
IN ANIMAL MODELS
When designing a preclinical in vivo study,  the  choice  of  animal  model  is
critical.  Small  animal models can be used for proof-of-principle testing,  but
testing of implantable medical devices and gaining of regulatory approval for
clinical trials requires cartilage thickness and joint size in which the device can
be implanted. In addition to the biological properties and translational value
of the animal model, the housing requirements and costs must be taken into
consideration. Many animal species used in in vivo models, such as rats and
rabbits, have capacity of spontaneous cartilage repair, unlike humans. This
creates a limitation that needs to be borne in mind in translational research.
Previous  study  by  Vasara  and  colleagues  (Vasara  et  al.  2006)  on  porcine
osteochondral defects showed that the spontaneous healing of skeletally
immature pigs is good with repair tissue rich in type II collagen, even though
the defects were 6 mm in diameter, which is considered the critical lesion size
in  porcine  cartilage  (Moran  et  al.  2016).  Our study I confirmed that
spontaneous healing of full-thickness chondral defects with the diameter of 8
mm  was  inferior  to  ACI-treated  defects.  The  small  study  groups  in  our
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feasibility study, however, resulted that the differences between the groups
were small and not statistically significant.
Critical osteochondral defect size in rabbit femur is 3×5 mm (Levingstone
et al. 2016, Moran et al. 2016). Although we created a large defect of 4 mm in
diameter and 8 mm in depth covering most of the medial femoral condyle of
rabbits,  no  large,  empty  voids  were  observed  in  the  spontaneously  repaired
defects. All untreated deep intra-articular bone defects in rabbits showed an
attempt  of  repair,  although  the  trabeculae  were  sparse  and  canals  from the
bone surface into the bone marrow spaces were not uncommon.
Similarly,  osteochondral  defects  in  the  horse  showed  subchondral  bone
changes still at 12 months post surgery. However, the overall filling of equine
osteochondral defects 2 mm in diameter did not differ from control tissue. This
repair tissue also showed good proteoglycan and type II collagen content in all
defect sizes. We concluded that the diameter of 4 mm should be considered
the critical osteochondral defect size in the equine carpus.
Previous studies evaluating critical cartilage defect size have focused on
evaluating the filling of the defects (Convery et al. 1972, Hurtig et al. 1988).
Although equine model has been used in cartilage repair research, long term
fate  of  the  spontaneously  formed  repair  tissue  in  the  equine  carpus  has
remained unknown. State-of-the-art methods, including MRI, μCT, polarized
light microscopy, standard histology and immunohistochemistry, were used
in evaluating equine cartilage repair in study III.  The  repair  tissue  of  the
chondral defects of all sizes demonstrated structural disorganization and loss
of proteoglycans and type II collagen staining. Defects with the diameter of 4
mm and 8 mm showed inadequate defect filling in the equine carpus. Smaller
defects  of  2  mm  demonstrated  lesion  filling  with  fibrocartilage.  As
fibrocartilage is prone to wearing out due to its inferior mechanical strength
to hyaline cartilage (Vachon et al. 1986), tissue quality needs to be analyzed
for objective evaluation of success. Based on the results of this study, 2 mm is
to be considered the critical chondral defect size in the equine carpus. These
new recommendations for the critical defect size allow for a more ethical use
of horse as a model in cartilage repair, as the defects are considerably smaller
than the previously recommended 9 mm, validated for the stifle joint (Russell
& Burch 1959, McIlwraith et al. 2011).
6.3 CONTRALATERAL LIMB IS AFFECTED BY
CARTILAGE DEFECTS
In animal models,  only one limb is  often used and the contralateral  limb is
used as a control, representing a healthy joint (Vasara et al. 2006, Pulkkinen
et  al.  2013b).  The  use  of  an  age-adjusted  healthy  control  group  with  no
interventions increases the number of animals used and therefore increases
costs  and  might  be  considered  to  contradict  the  Reduction  principle  of  the
three R’s (Russell & Burch 1959). However, the biomechanical testing in the
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porcine study (study I) showed that untreated cartilage defects resulted in
considerably higher cartilage permeability to water in the contralateral non-
operated limb than the non-operated limbs of the treatment groups. This
indicates a worsened tissue quality with loss of proteoglycans (Korhonen et al.
2003).  It  is  possible  that  an  altered  loading  pattern,  due  to  pain  or  lack  of
mechanical support, might have promoted this change (Kiviranta et al. 1994,
Vanwanseele et al. 2003), even though deviant limping of the animals in the
untreated group was not detected during the study period.
Studies I and II were  limited  by  the  lack  of  a  healthy  control  group.
However, in both studies, the comparison of different study groups is possible
as all  groups used the non-operated limb as an animal-specific  control.  The
use of a healthy control group with no interventions is recommended in order
to see the real effect of the treatment.
6.4 SUBCHONDRAL BONE CYSTS ASSOCIATED WITH
CARTILAGE DEFECTS IN ANIMAL MODELS
Subchondral  bone  cysts  are  common  after  cartilage  procedures.  They  have
been reported both in patients (Vasiliadis et al. 2010, Orth et al. 2013) and in
animal models (Vasara et al. 2004, Orth et al. 2013). Porcine subchondral
bone is soft and immature porcine cartilage lacks calcified layer (Vasara et al.
2006, Li et al. 2009). Therefore, it might easily lead to sinking of the scaffold
material  into  the  bone,  as  seen  in  one  animal  in study I. In this porcine
experiment, in which all articular cartilage was removed and the subchondral
bone was exposed, bone cysts were seen both in the treatment groups and the
spontaneously  healed  control  group.  In  a  previous  study,  the  softness  of
porcine subchondral bone plate as a risk factor for bone cysts was discussed in
more detail (Vasara et al. 2006). However, the spontaneously healed group in
study I showed less  and  smaller  bone  cysts  than  the  two  augmented  repair
groups.
In the equine study (study III), the surgically created osteochondral defects
extended  approximately  2─3 mm  into  the  subchondral  bone.  Although  the
defects  2  mm  in  diameter  showed  good  filling  with  repair  tissue,  4/5
specimens showed bone pathologies 12 months post-surgery. This
demonstrates poblems in subchondral bone repair even in the small defects.
Shallow chondral lesions in the equine carpus presented with no subchondral
bone cysts. This is in line with previous studies that conclude that bone cysts
commonly arise after  disruption of  the subchondral  plate in the equine and
caprine  model  (Hurtig  et  al.  2011)(Jackson  et  al.  2001).  As  the  porcine
cartilage lacks the calcified layer, full-thickness chondral porcine defects can
be seen as osteochondral in nature. Our study shows that both augmented and
spontaneous repair of osteochondral defects lead to cysts and other bone voids
in different large animal models.
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Trabecular bone structure varied between the different animals. The equine
model showed thinner and denser trabecular structure compared to the two
other animal species. Both the porcine and equine trabecular parameters in
this study (Table 7) are in line with previously published values (Furst et al.
2008, Holzer et al. 2012). Trabecular thickness and spacing in the rabbit was
larger in this study than in previous reports (Voor et al. 2008), probably due
to the large voids in the analyzed area.
Thickened  trabeculae  have  been  associated  both  with  early  OA  and
increased  joint  loading  (Ding  et  al.  2003).  In study I, pigs with iatrogenic
cartilage lesions showed thickened trabeculae underneath the cartilage defect,
compared to non-operated contralateral limbs but their separation and
number  was  close  to  non-operated  knees.  Similarly,  in  deep  intra-articular
bone  defects  in  the  rabbits  of study II,  the  bone  trabeculae  of  the
spontaneously healed defects were thick and sparse and thus differed from the
contralateral healthy knees.
It seems that disruption of the cartilage layer, whether iatrogenic or natural,
leads to these trabecular structural changes. However, in the equine model
(study III)  where  tissue  adjacent  to  the  defects  was  used  as  control,  the
trabecular thickness of the bone underneath the cartilage defects and adjacent
tissue did not differ from one another. This may suggest that the changes in
the  subchondral  bone  trabecular  architecture  are  due  to  altered  loading
conditions, rather than a local or a direct effect of the defect on the underlying
bone.
6.5 FEASIBILITY OF THE NOVEL RHCO-PLA SCAFFOLD
The repaired cartilage tissue in both the novel rhCo-PLA scaffold and the well-
established commercial pCo membrane showed similar structure
histologically  and biochemically  in the porcine study (study I). However, in
the in vitro study  (study IV), in which human chondrocytes and BM-MSCs
were cultured in the scaffolds, porcine type I/III collagen membrane induced
cartilage hypertrophy and osteogenic commitment at a higher level than the
three-dimensional rhCo-PLA scaffolds, shown by upregulation of osteogenic
genes COL10A2 and RUNX2. The type of recombinant human collagen used
in the manufacturing of the rhCo-PLA scaffolds did not affect the results. This
implicates that the three-dimensional structure might be more important for
the cell fate than the type of protein component used in the scaffold.
The results of study I showed promising in vivo results with the novel rhCo-
PLA scaffold. Treatment of porcine cartilage defects with the rhCo-PLA
implant resulted in fewer bone cysts  than treatment with porcine type I/III
collagen membrane. This is probably due to the porous structure of rhCo-PLA
which  allows  for  a  natural  multidirectional  fluid  flow during  cyclic  loading,
unlike the collagen membrane in which one side is  hydrophilic,  intended to
keep the cells in place. This membrane might function as a valve, filling the
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defect site with synovial fluid but restricting its backword flow. As fluids are
incompressible, each loading cycle during the joint movement presses the fluid
into the slit, thus expanding it into the subchondral bone (Kold et al. 1986).
6.6 BONE FILLERS IN REPAIR OF DEEP
OSTEOCHONDRAL DEFECTS
Creating  biodegradable  cylindrical  plugs  to  fill  the  bony  part  of  a  deep
osteochondral defect was hypothesized to result in joint reconstruction, to
ultimately be used in biological joint repair instead of conventional joint
replacement surgery. Filling of deep osteochondral defects in rabbits with the
gas-foamed PLGA scaffold in study II resulted in repair  worse or similar to
spontaneous healing. PLGA induced a mild inflammatory response in the
treated defects as seen by the presence of inflammatory cells, which is probably
due to the acidic surrounding caused by its degradation (Gentile et al. 2014,
Haaparanta et al. 2015).
In study II, granular bone fillers did not erode from the defect site during
the 3-month follow-up. Extensive bone defect filling with mineralized tissue
was observed in both the β-TCP and BG-treated groups. A small depression
was  detected  on  the  surface,  indicating  sagging  of  the  granules.  Bone
architecture in the granule-treated groups was similar to non-operated
controls. Thus, the granular bone substitutes might have the potential to be
used in the repair of the bony part of deep osteochondral defects.
Bioactive glass has provided good results in terms of osteoconduction
(Lindfors  et  al.  2009).  In  our  study,  bioactive  glass  alone  showed  bone
trabecular parameters that were closest to those of the non-operated
contralateral limbs, indicating good overall repair tissue quality. Brittleness of
bioactive glass has limited its use in weight-bearing applications but
combining  it  with  polymers  has  been  reported  to  improve  the  mechanical
properties of the construct (El-Rashidy et al. 2017). Surprisingly, PLGA
combined with bioactive glass fibers in study II worsened the repair result as
the  defects  were  filled  with  loose  connective  tissue  rather  than  osteoid  or
mineralized bone. A possible explanation might be that the porosity of both
PLGA-based scaffolds might have been compromised by collapse of the pores
and the small size of the pores (Haaparanta et al. 2015, Uppstu et al. 2015).
Although this study focused on the bony part of the defect, it needs to be stated
that  none  of  the  studied  materials  was  capable  of  restoring  the  cartilage
surface in the lapine model. Therefore, a separate cartilage restorative
procedure should be considered on top of the bone repair to restore the joint
surface.
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6.7 SYNOVIAL JOINT AS A FUNCTIONAL UNIT
A synovial joint comprises a functional unit in which all its parts play a crucial
role. Malalignment and damage to stabilizing ligaments and menisci have
been  shown  to  lead  to  cartilage  defects  (Gomoll  et  al.  2010,  Sharma  et  al.
2010). Similarly, the importance of crosstalk between articular cartilage and
subchondral bone has been acknowledged (Pan et al. 2009, Orth et al. 2013,
Findlay & Kuliwaba 2016).
Lack  of  support  from the  subchondral  bone  underneath  cartilage  defects
lead to increased loading on the surrounding articular cartilage (Jackson et al.
2001). This might lead to early degeneration of the cartilage adjacent to the
defect site. Shallow chondral defects created in the equine carpus in study III
did  not  present  with  subchondral  bone  cysts,  but  deeper  osteochondral
defects,  in  which  the  subchondral  bone  plate  was  disrupted,  did.
Correspondingly, deep osteochondral defects in the lapine model showed very
little cartilage formation on the joint surface even in the defects repaired with
granular commercial bone substitutes that resulted in satisfactory bone repair.
Although rabbits typically possess good intrinsic healing capacity (Ahern et al.
2009,  Moran  et  al.  2016),  absence  of  a  separate  cartilage  regenerative
procedure hampered the repair of articular cartilage. Similar results were
noted in minipigs where osteochondral defects repaired with PLGA-
hydroxyapatite-β-TCP scaffolds (Matsuo et al. 2015).
Although the mechanical support of subchondral bone is needed for proper
cartilage repair, the connection between the disrupted cartilage and bone
marrow spaces  seem important  for  the  repair  of  chondral  defects.  This  was
noted in study I, in which one chondral defect did not reach the subchondral
bone  plate  (animal  25,  rhCo-PLA  group).  In  spite  of  5.6×106 autologous
chondrocytes being implanted with the rhCo-PLA scaffold on the defect site
with a diameter of 8 mm, no hyaline cartilage was formed. This cell amount is
11.2×106 cells/cm2, more than double the amount of cells used in the original
ACI procedure by Brittberg and colleagues in which 2.6–5.0 ×106 cells were
used in cartilage defects with a mean size of 3.1 cm2 (Brittberg et al. 1994). The
amount of autologous chondrocytes implanted to defect site in clinical studies
varies between 0.5–12×106 (Foldager et al. 2012). Therefore, the mesenchymal
stem cells and trophic factors originating from marrow spaces and repair of
the entire osteochondral unit seem important for cartilage regeneration as
previously proposed (Murphy et al. 2013, Caplan 2017, de Vries-van Melle et
al. 2014).
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6.8 FUTURE PROSPECTS
Articular cartilage repair constitutes an immense challenge. Although the Holy
Grail of cartilage repair still remains to be discovered, progress has been made
in terms of better understanding the tissue structure and behavior. Articular
cartilage  and  subchondral  bone  have  an  effect  on  one  another.  The  exact
mechanism  of  the  cross-talk  between  the  bone  and  cartilage  in  humans  is,
however, still unknown. Finding out the mechanism would probably be highly
valuable in developing articular cartilage repair.
Biomaterial scaffolds have been extensively studied but no material has
proven superiority over another. The novel rhCo-PLA scaffold showed
promising  results  in  the  feasibility  study  in  the  porcine  model  but  further
studies, including a healthy control group, are required in order to confirm the
safety and the efficacy of the scaffold.
The pilot cell pellet study of study IV and previous studies both with human
(Georgi  et  al.  2015,  Skog  et  al.  2015)  and  animal  MSCs  (Zayed  et  al.  2017)
showed  that  the  chondrogenic  potential  of  human  mesenchymal  stem  cells
varies between individual donors. A study investigating the chondrogenic
potential of BM-MSCs in patients with and without PTOA after knee trauma
might be able to provide insight about the regenerative potential of articular
cartilage.
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7 CONCLUSIONS
In  this  study,  cartilage  repair  with  novel  biomaterial  scaffolds  and  cell
therapies was investigated using both in vitro and animal models. Based on
the results, the specific conclusions are the following:
1 The  new  composite  biomaterial  rhCo-PLA  showed  fewer  bone
cysts  but  similar  cartilage  repair  tissue  to  that  obtained  with
commercial pCo membrane. Thus, the new biomaterial rhCo-PLA
seems to be suitable for the repair of chondral defects with the ACI
method.
2 The new PLGA-based biomaterials are insufficient in the repair of
deep osteochondral lesions. Repair tissue produced with these
materials was similar to or worse than spontaneous repair.
3 Spontaneous  defect  healing  in  the  equine  carpus  is  more
restricted than previously thought. The new proposed critical
lesion  size  for  chondral  lesions  is  2  mm  in  diameter  and  for
osteochondral lesions 4 mm in diameter in the equine carpus.
4 Chondrogenic differentiation of BM-MSCs was not successful in
the  rhCo-PLA  or  the  pCo  scaffolds in vitro. The chondrogenic
differentiation lead to cell hypertrophy.
This  study  demonstrated  the  capacity  of  the  novel  rhCo-PLA  scaffold  to
produce  hyaline  cartilage  in  a  porcine  model.  However,  subchondral  bone
defects in association with cartilage repair procedures and surgically created
osteochondral defects were common in pigs (study I), rabbits (study II), and
in horses (study III).
As seen in study I, non-operated contralateral limb is also affected by the
defect and repair procedure. Untreated cartilage defect leads to an increased
cartilage permeability to water in the contralateral limb.
Synovial joints comprise a functional unit in which each component is to be
taken  into  consideration.  Successful  chondral  repair  is  jeopardized  if  the
integrity  of  the  subchondral  bone  is  compromised.  Similarly,  repair  of  the
bony part of an osteochondral defect requires an additional repair of articular
cartilage in order to restore joint health.
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